ID
DB08971||
名称
Fluocortolone
描述
Fluocortolone is a glucocorticoid with anti-inflammatory activity used topically for various skin disorders.
cas号
152-97-6
唯一标识码
65VXC1MH0J
状态
solid
一般参考文献


approved,withdrawn,
指示
药效学
作用机制
毒性
代谢
吸收
半衰期
分类
description:This compound belongs to the class of organic compounds known as 21-hydroxysteroids. These are steroids carrying a hydroxyl group at the 21-position of the steroid backbone.
direct-parent:21-hydroxysteroids
kingdom:Organic compounds
superclass:Lipids and lipid-like molecules
class:Steroids and steroid derivatives
subclass:Hydroxysteroids
alternative-parent:11-beta-hydroxysteroids
alternative-parent:20-oxosteroids
alternative-parent:3-oxo delta-1,4-steroids
alternative-parent:Alkyl fluorides
alternative-parent:Alpha-hydroxy ketones
alternative-parent:Cyclic alcohols and derivatives
alternative-parent:Cyclic ketones
alternative-parent:Delta-1,4-steroids
alternative-parent:Gluco/mineralocorticoids, progestogins and derivatives
alternative-parent:Halogenated steroids
alternative-parent:Hydrocarbon derivatives
alternative-parent:Organic oxides
alternative-parent:Organofluorides
alternative-parent:Primary alcohols
alternative-parent:Secondary alcohols
substituent:11-beta-hydroxysteroid
substituent:11-hydroxysteroid
substituent:20-oxosteroid
substituent:21-hydroxysteroid
substituent:3-oxo-delta-1,4-steroid
substituent:3-oxosteroid
substituent:6-halo-steroid
substituent:Alcohol
substituent:Aliphatic homopolycyclic compound
substituent:Alkyl fluoride
substituent:Alkyl halide
substituent:Alpha-hydroxy ketone
substituent:Carbonyl group
substituent:Cyclic alcohol
substituent:Cyclic ketone
substituent:Delta-1,4-steroid
substituent:Halo-steroid
substituent:Hydrocarbon derivative
substituent:Ketone
substituent:Organic oxide
substituent:Organic oxygen compound
substituent:Organofluoride
substituent:Organohalogen compound
substituent:Organooxygen compound
substituent:Oxosteroid
substituent:Pregnane-skeleton
substituent:Primary alcohol
substituent:Progestogin-skeleton
substituent:Secondary alcohol
消除途径
种类
Adrenal Cortex Hormones
D000305
Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use

Anti-Inflammatory Agents
D000893
Corticosteroids
D000305
Corticosteroids for Systemic Use, Plain

Corticosteroids, Dermatological Preparations

Corticosteroids, Potent (Group III)

Cytochrome P-450 CYP3A Inducers
D065701
Cytochrome P-450 CYP3A Substrates

Cytochrome P-450 CYP3A4 Inducers
D065701
Cytochrome P-450 CYP3A4 Inducers (strength unknown)

Cytochrome P-450 CYP3A4 Substrates

Cytochrome P-450 CYP3A5 Inducers
D065701
Cytochrome P-450 CYP3A5 Inducers (strength unknown)

Cytochrome P-450 Enzyme Inducers
D065693
Cytochrome P-450 Substrates

Dermatologicals
D003879
Fused-Ring Compounds
D000072473
Glucocorticoids
D005938
Hormones
D006728
Hormones, Hormone Substitutes, and Hormone Antagonists
D006730
Hyperglycemia-Associated Agents

Immunosuppressive Agents
D007166
Ophthalmologicals

Pregnadienediols
D011244
Pregnadienes
D011245
Pregnanes
D011278
Sensory Organs

Steroids
D013256
Steroids, Fluorinated
D013259
Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins

Vasoprotectives

盐类
蛋白质结合
清除
同义词
language:spanish; code:; name;Fluocortolona
国际品牌
配送量
产品
混合物
包装者
生产者
价格
受影响的生物体
剂量
form:Cream
route:Topical
strength:0.25 %
form:Tablet
route:Oral
strength:5 mg
form:Ointment
route:Topical
strength:0.25 %
form:Tablet
route:
strength:20 mg
atc代码
Corticosteroids, potent (group III)
CORTICOSTEROIDS, PLAIN
CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS
DERMATOLOGICALS
Corticosteroids, potent, combinations with antiseptics
CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS
CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS
DERMATOLOGICALS
Corticosteroids, potent, combinations with antibiotics
CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS
CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS
DERMATOLOGICALS
Corticosteroids and antiinfectives in combination
ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION
OPHTHALMOLOGICALS
SENSORY ORGANS
Corticosteroids, potent, other combinations
CORTICOSTEROIDS, OTHER COMBINATIONS
CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS
DERMATOLOGICALS
Glucocorticoids
CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN
CORTICOSTEROIDS FOR SYSTEMIC USE
SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS
Corticosteroids
AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE
VASOPROTECTIVES
CARDIOVASCULAR SYSTEM
fda标签
化学品安全技术说明书
专利
食物相互作用
药物相互作用
DB06643
The risk or severity of adverse effects can be increased when Denosumab is combined with Fluocortolone.
DB00005
The risk or severity of adverse effects can be increased when Etanercept is combined with Fluocortolone.
DB00008
The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Fluocortolone.
DB00011
The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Fluocortolone.
DB00018
The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Fluocortolone.
DB00022
The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Fluocortolone.
DB00026
The risk or severity of adverse effects can be increased when Anakinra is combined with Fluocortolone.
DB00033
The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Fluocortolone.
DB00034
The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Fluocortolone.
DB00051
The risk or severity of adverse effects can be increased when Adalimumab is combined with Fluocortolone.
DB00056
The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Fluocortolone.
DB00059
The risk or severity of adverse effects can be increased when Pegaspargase is combined with Fluocortolone.
DB00065
The risk or severity of adverse effects can be increased when Infliximab is combined with Fluocortolone.
DB00068
The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Fluocortolone.
DB00069
The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Fluocortolone.
DB00073
The risk or severity of adverse effects can be increased when Rituximab is combined with Fluocortolone.
DB00074
The risk or severity of adverse effects can be increased when Basiliximab is combined with Fluocortolone.
DB00075
The risk or severity of adverse effects can be increased when Muromonab is combined with Fluocortolone.
DB00078
The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fluocortolone.
DB00081
The risk or severity of adverse effects can be increased when Tositumomab is combined with Fluocortolone.
DB00087
The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Fluocortolone.
DB00092
The risk or severity of adverse effects can be increased when Alefacept is combined with Fluocortolone.
DB00095
The risk or severity of adverse effects can be increased when Efalizumab is combined with Fluocortolone.
DB00098
The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Fluocortolone.
DB00105
The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Fluocortolone.
DB00111
The risk or severity of adverse effects can be increased when Daclizumab is combined with Fluocortolone.
DB00112
The risk or severity of adverse effects can be increased when Bevacizumab is combined with Fluocortolone.
DB00120
The risk or severity of adverse effects can be increased when Phenylalanine is combined with Fluocortolone.
DB00180
The risk or severity of adverse effects can be increased when Flunisolide is combined with Fluocortolone.
DB00242
The risk or severity of adverse effects can be increased when Cladribine is combined with Fluocortolone.
DB00262
The risk or severity of adverse effects can be increased when Carmustine is combined with Fluocortolone.
DB00276
The risk or severity of adverse effects can be increased when Amsacrine is combined with Fluocortolone.
DB00290
The risk or severity of adverse effects can be increased when Bleomycin is combined with Fluocortolone.
DB00291
The risk or severity of adverse effects can be increased when Chlorambucil is combined with Fluocortolone.
DB00293
The risk or severity of adverse effects can be increased when Raltitrexed is combined with Fluocortolone.
DB00305
The risk or severity of adverse effects can be increased when Mitomycin is combined with Fluocortolone.
DB00307
The risk or severity of adverse effects can be increased when Bexarotene is combined with Fluocortolone.
DB00322
The risk or severity of adverse effects can be increased when Floxuridine is combined with Fluocortolone.
DB00352
The risk or severity of adverse effects can be increased when Tioguanine is combined with Fluocortolone.
DB00380
The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Fluocortolone.
DB00394
The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Fluocortolone.
DB00428
The risk or severity of adverse effects can be increased when Streptozocin is combined with Fluocortolone.
DB00432
The risk or severity of adverse effects can be increased when Trifluridine is combined with Fluocortolone.
DB00441
The risk or severity of adverse effects can be increased when Gemcitabine is combined with Fluocortolone.
DB00443
The risk or severity of adverse effects can be increased when Betamethasone is combined with Fluocortolone.
DB00445
The risk or severity of adverse effects can be increased when Epirubicin is combined with Fluocortolone.
DB00446
The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Fluocortolone.
DB00480
The risk or severity of adverse effects can be increased when Lenalidomide is combined with Fluocortolone.
DB00488
The risk or severity of adverse effects can be increased when Altretamine is combined with Fluocortolone.
DB00495
The risk or severity of adverse effects can be increased when Zidovudine is combined with Fluocortolone.
DB00526
The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Fluocortolone.
DB00544
The risk or severity of adverse effects can be increased when Fluorouracil is combined with Fluocortolone.
DB00547
The risk or severity of adverse effects can be increased when Desoximetasone is combined with Fluocortolone.
DB00550
The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Fluocortolone.
DB00552
The risk or severity of adverse effects can be increased when Pentostatin is combined with Fluocortolone.
DB00588
The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Fluocortolone.
DB00591
The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Fluocortolone.
DB00601
The risk or severity of adverse effects can be increased when Linezolid is combined with Fluocortolone.
DB00620
The risk or severity of adverse effects can be increased when Triamcinolone is combined with Fluocortolone.
DB00631
The risk or severity of adverse effects can be increased when Clofarabine is combined with Fluocortolone.
DB00635
The risk or severity of adverse effects can be increased when Prednisone is combined with Fluocortolone.
DB00642
The risk or severity of adverse effects can be increased when Pemetrexed is combined with Fluocortolone.
DB00687
The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Fluocortolone.
DB00688
The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Fluocortolone.
DB00694
The risk or severity of adverse effects can be increased when Daunorubicin is combined with Fluocortolone.
DB00755
The risk or severity of adverse effects can be increased when Tretinoin is combined with Fluocortolone.
DB00763
The risk or severity of adverse effects can be increased when Methimazole is combined with Fluocortolone.
DB00764
The risk or severity of adverse effects can be increased when Mometasone is combined with Fluocortolone.
DB00851
The risk or severity of adverse effects can be increased when Dacarbazine is combined with Fluocortolone.
DB00853
The risk or severity of adverse effects can be increased when Temozolomide is combined with Fluocortolone.
DB00859
The risk or severity of adverse effects can be increased when Penicillamine is combined with Fluocortolone.
DB00860
The risk or severity of adverse effects can be increased when Prednisolone is combined with Fluocortolone.
DB00928
The risk or severity of adverse effects can be increased when Azacitidine is combined with Fluocortolone.
DB00958
The risk or severity of adverse effects can be increased when Carboplatin is combined with Fluocortolone.
DB00959
The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Fluocortolone.
DB00970
The risk or severity of adverse effects can be increased when Dactinomycin is combined with Fluocortolone.
DB00987
The risk or severity of adverse effects can be increased when Cytarabine is combined with Fluocortolone.
DB00993
The risk or severity of adverse effects can be increased when Azathioprine is combined with Fluocortolone.
DB01005
The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Fluocortolone.
DB01013
The risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Fluocortolone.
DB01024
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Fluocortolone.
DB01030
The risk or severity of adverse effects can be increased when Topotecan is combined with Fluocortolone.
DB01033
The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Fluocortolone.
DB01041
The risk or severity of adverse effects can be increased when Thalidomide is combined with Fluocortolone.
DB01042
The risk or severity of adverse effects can be increased when Melphalan is combined with Fluocortolone.
DB01047
The risk or severity of adverse effects can be increased when Fluocinonide is combined with Fluocortolone.
DB01073
The risk or severity of adverse effects can be increased when Fludarabine is combined with Fluocortolone.
DB01099
The risk or severity of adverse effects can be increased when Flucytosine is combined with Fluocortolone.
DB01101
The risk or severity of adverse effects can be increased when Capecitabine is combined with Fluocortolone.
DB01168
The risk or severity of adverse effects can be increased when Procarbazine is combined with Fluocortolone.
DB01169
The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Fluocortolone.
DB01177
The risk or severity of adverse effects can be increased when Idarubicin is combined with Fluocortolone.
DB01196
The risk or severity of adverse effects can be increased when Estramustine is combined with Fluocortolone.
DB01204
The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Fluocortolone.
DB01206
The risk or severity of adverse effects can be increased when Lomustine is combined with Fluocortolone.
DB01222
The risk or severity of adverse effects can be increased when Budesonide is combined with Fluocortolone.
DB01234
The risk or severity of adverse effects can be increased when Dexamethasone is combined with Fluocortolone.
DB01257
The risk or severity of adverse effects can be increased when Eculizumab is combined with Fluocortolone.
DB01262
The risk or severity of adverse effects can be increased when Decitabine is combined with Fluocortolone.
DB01280
The risk or severity of adverse effects can be increased when Nelarabine is combined with Fluocortolone.
DB01281
The risk or severity of adverse effects can be increased when Abatacept is combined with Fluocortolone.
DB01285
The risk or severity of adverse effects can be increased when Corticotropin is combined with Fluocortolone.
DB01380
The risk or severity of adverse effects can be increased when Cortisone acetate is combined with Fluocortolone.
DB01384
The risk or severity of adverse effects can be increased when Paramethasone is combined with Fluocortolone.
DB01394
The risk or severity of adverse effects can be increased when Colchicine is combined with Fluocortolone.
DB01410
The risk or severity of adverse effects can be increased when Ciclesonide is combined with Fluocortolone.
DB01423
The risk or severity of adverse effects can be increased when Stepronin is combined with Fluocortolone.
DB01611
The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Fluocortolone.
DB01816
The risk or severity of adverse effects can be increased when Castanospermine is combined with Fluocortolone.
DB02546
The risk or severity of adverse effects can be increased when Vorinostat is combined with Fluocortolone.
DB02806
The risk or severity of adverse effects can be increased when 2-Methoxyethanol is combined with Fluocortolone.
DB03523
The risk or severity of adverse effects can be increased when Brequinar is combined with Fluocortolone.
DB04630
The risk or severity of adverse effects can be increased when Aldosterone is combined with Fluocortolone.
DB04951
The risk or severity of adverse effects can be increased when Pirfenidone is combined with Fluocortolone.
DB04956
The risk or severity of adverse effects can be increased when Afelimomab is combined with Fluocortolone.
DB05015
The risk or severity of adverse effects can be increased when Belinostat is combined with Fluocortolone.
DB05258
The risk or severity of adverse effects can be increased when Interferon alfa is combined with Fluocortolone.
DB05259
The risk or severity of adverse effects can be increased when Glatiramer is combined with Fluocortolone.
DB05260
The risk or severity of adverse effects can be increased when Gallium nitrate is combined with Fluocortolone.
DB05459
The risk or severity of adverse effects can be increased when Briakinumab is combined with Fluocortolone.
DB05472
The risk or severity of adverse effects can be increased when Human interferon omega-1 is combined with Fluocortolone.
DB05676
The risk or severity of adverse effects can be increased when Apremilast is combined with Fluocortolone.
DB06168
The risk or severity of adverse effects can be increased when Canakinumab is combined with Fluocortolone.
DB06273
The risk or severity of adverse effects can be increased when Tocilizumab is combined with Fluocortolone.
DB06372
The risk or severity of adverse effects can be increased when Rilonacept is combined with Fluocortolone.
DB06612
The risk or severity of adverse effects can be increased when Mepolizumab is combined with Fluocortolone.
DB06662
The risk or severity of adverse effects can be increased when Abetimus is combined with Fluocortolone.
DB06674
The risk or severity of adverse effects can be increased when Golimumab is combined with Fluocortolone.
DB06681
The risk or severity of adverse effects can be increased when Belatacept is combined with Fluocortolone.
DB06769
The risk or severity of adverse effects can be increased when Bendamustine is combined with Fluocortolone.
DB06813
The risk or severity of adverse effects can be increased when Pralatrexate is combined with Fluocortolone.
DB08059
The risk or severity of adverse effects can be increased when Wortmannin is combined with Fluocortolone.
DB08871
The risk or severity of adverse effects can be increased when Eribulin is combined with Fluocortolone.
DB08879
The risk or severity of adverse effects can be increased when Belimumab is combined with Fluocortolone.
DB08880
The risk or severity of adverse effects can be increased when Teriflunomide is combined with Fluocortolone.
DB08889
The risk or severity of adverse effects can be increased when Carfilzomib is combined with Fluocortolone.
DB08904
The risk or severity of adverse effects can be increased when Certolizumab pegol is combined with Fluocortolone.
DB08906
The risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Fluocortolone.
DB08908
The risk or severity of adverse effects can be increased when Dimethyl fumarate is combined with Fluocortolone.
DB08935
The risk or severity of adverse effects can be increased when Obinutuzumab is combined with Fluocortolone.
DB08970
The risk or severity of adverse effects can be increased when Fluprednidene is combined with Fluocortolone.
DB09029
The risk or severity of adverse effects can be increased when Fluocortolone is combined with Secukinumab.
DB09033
The risk or severity of adverse effects can be increased when Fluocortolone is combined with Vedolizumab.
DB09036
The risk or severity of adverse effects can be increased when Fluocortolone is combined with Siltuximab.
DB09052
The risk or severity of adverse effects can be increased when Fluocortolone is combined with Blinatumomab.
DB09077
The risk or severity of adverse effects can be increased when Fluocortolone is combined with Dinutuximab.
DB09082
The risk or severity of adverse effects can be increased when Fluocortolone is combined with Vilanterol.
DB09091
The risk or severity of adverse effects can be increased when Fluocortolone is combined with Tixocortol.
DB09122
The risk or severity of adverse effects can be increased when Fluocortolone is combined with Peginterferon beta-1a.
DB09312
The risk or severity of adverse effects can be increased when Fluocortolone is combined with Antilymphocyte immunoglobulin (horse).
DB09378
The risk or severity of adverse effects can be increased when Fluocortolone is combined with Fluprednisolone.
DB09383
The risk or severity of adverse effects can be increased when Fluocortolone is combined with Meprednisone.
DB11487
The risk or severity of adverse effects can be increased when Fluocortolone is combined with Dexamethasone isonicotinate.
DB11529
The risk or severity of adverse effects can be increased when Fluocortolone is combined with Melengestrol.
DB11569
The risk or severity of adverse effects can be increased when Fluocortolone is combined with Ixekizumab.
DB11580
The risk or severity of adverse effects can be increased when Fluocortolone is combined with Ravulizumab.
DB11616
The risk or severity of adverse effects can be increased when Fluocortolone is combined with Pirarubicin.
DB11693
The risk or severity of adverse effects can be increased when Fluocortolone is combined with Voclosporin.
DB11708
The risk or severity of adverse effects can be increased when Fluocortolone is combined with Peficitinib.
DB11750
The risk or severity of adverse effects can be increased when Fluocortolone is combined with Clobetasol.
DB11767
The risk or severity of adverse effects can be increased when Fluocortolone is combined with Sarilumab.
DB11776
The risk or severity of adverse effects can be increased when Fluocortolone is combined with Brodalumab.
DB11803
The risk or severity of adverse effects can be increased when Fluocortolone is combined with Sirukumab.
DB11834
The risk or severity of adverse effects can be increased when Fluocortolone is combined with Guselkumab.
DB11921
The risk or severity of adverse effects can be increased when Fluocortolone is combined with Deflazacort.
DB11988
The risk or severity of adverse effects can be increased when Fluocortolone is combined with Ocrelizumab.
DB12612
The risk or severity of adverse effects can be increased when Fluocortolone is combined with Ozanimod.
DB12617
The risk or severity of adverse effects can be increased when Fluocortolone is combined with Mizoribine.
DB12692
The risk or severity of adverse effects can be increased when Fluocortolone is combined with Gusperimus.
DB12814
The risk or severity of adverse effects can be increased when Fluocortolone is combined with Cepeginterferon alfa-2B.
DB12902
The risk or severity of adverse effects can be increased when Fluocortolone is combined with Trofosfamide.
DB12947
The risk or severity of adverse effects can be increased when Fluocortolone is combined with Doxifluridine.
DB12991
The risk or severity of adverse effects can be increased when Fluocortolone is combined with Deoxyspergualin.
DB12996
The risk or severity of adverse effects can be increased when Fluocortolone is combined with Acteoside.
DB13003
The risk or severity of adverse effects can be increased when Fluocortolone is combined with Cortivazol.
DB13014
The risk or severity of adverse effects can be increased when Fluocortolone is combined with Hypericin.
DB13068
The risk or severity of adverse effects can be increased when Fluocortolone is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
DB13208
The risk or severity of adverse effects can be increased when Fluocortolone is combined with Prednylidene.
DB13223
The risk or severity of adverse effects can be increased when Fluocortolone is combined with Fluocortin.
DB13241
The risk or severity of adverse effects can be increased when Fluocortolone is combined with Begelomab.
DB13491
The risk or severity of adverse effects can be increased when Fluocortolone is combined with Fluperolone.
DB13843
The risk or severity of adverse effects can be increased when Fluocortolone is combined with Cloprednol.
DB13856
The risk or severity of adverse effects can be increased when Fluocortolone is combined with Fluclorolone.
DB13867
The risk or severity of adverse effects can be increased when Fluocortolone is combined with Fluticasone.
DB14066
The risk or severity of adverse effects can be increased when Fluocortolone is combined with Tetrandrine.
DB14219
The risk or severity of adverse effects can be increased when Fluocortolone is combined with Monomethyl fumarate.
DB14512
The risk or severity of adverse effects can be increased when Fluocortolone is combined with Mometasone furoate.
DB14539
The risk or severity of adverse effects can be increased when Fluocortolone is combined with Hydrocortisone acetate.
DB14540
The risk or severity of adverse effects can be increased when Fluocortolone is combined with Hydrocortisone butyrate.
DB14545
The risk or severity of adverse effects can be increased when Fluocortolone is combined with Hydrocortisone succinate.
DB14724
The risk or severity of adverse effects can be increased when Fluocortolone is combined with Emapalumab.
DB14762
The risk or severity of adverse effects can be increased when Fluocortolone is combined with Risankizumab.
DB14919
The risk or severity of adverse effects can be increased when Fluocortolone is combined with Rozanolixizumab.
DB15253
The risk or severity of adverse effects can be increased when Fluocortolone is combined with Bleselumab.
DB00619
The risk or severity of adverse effects can be increased when Fluocortolone is combined with Imatinib.
DB09053
The risk or severity of adverse effects can be increased when Fluocortolone is combined with Ibrutinib.
DB00324
The risk or severity of adverse effects can be increased when Fluorometholone is combined with Fluocortolone.
DB09095
The risk or severity of adverse effects can be increased when Fluocortolone is combined with Difluocortolone.
DB00108
The risk or severity of adverse effects can be increased when Natalizumab is combined with Fluocortolone.
DB00337
The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Fluocortolone.
DB01656
Roflumilast may increase the immunosuppressive activities of Fluocortolone.
DB06688
The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Fluocortolone.
DB09063
The risk or severity of hyperglycemia can be increased when Fluocortolone is combined with Ceritinib.
DB00041
The therapeutic efficacy of Fluocortolone can be decreased when used in combination with Aldesleukin.
DB09067
The therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Fluocortolone.
DB01609
The risk or severity of gastrointestinal ulceration and gastrointestinal irritation can be increased when Fluocortolone is combined with Deferasirox.
DB00681
The risk or severity of hypokalemia can be increased when Fluocortolone is combined with Amphotericin B.
DB00221
The risk or severity of hypokalemia can be increased when Fluocortolone is combined with Isoetharine.
DB00368
The risk or severity of hypokalemia can be increased when Fluocortolone is combined with Norepinephrine.
DB00397
The risk or severity of hypokalemia can be increased when Fluocortolone is combined with Phenylpropanolamine.
DB00668
The risk or severity of hypokalemia can be increased when Fluocortolone is combined with Epinephrine.
DB00816
The risk or severity of hypokalemia can be increased when Fluocortolone is combined with Orciprenaline.
DB00841
The risk or severity of hypokalemia can be increased when Fluocortolone is combined with Dobutamine.
DB00867
The risk or severity of hypokalemia can be increased when Fluocortolone is combined with Ritodrine.
DB00901
The risk or severity of hypokalemia can be increased when Fluocortolone is combined with Bitolterol.
DB00938
The risk or severity of hypokalemia can be increased when Fluocortolone is combined with Salmeterol.
DB00983
The risk or severity of hypokalemia can be increased when Fluocortolone is combined with Formoterol.
DB01001
The risk or severity of hypokalemia can be increased when Fluocortolone is combined with Salbutamol.
DB01064
The risk or severity of hypokalemia can be increased when Fluocortolone is combined with Isoprenaline.
DB01102
The risk or severity of hypokalemia can be increased when Fluocortolone is combined with Arbutamine.
DB01274
The risk or severity of hypokalemia can be increased when Fluocortolone is combined with Arformoterol.
DB01288
The risk or severity of hypokalemia can be increased when Fluocortolone is combined with Fenoterol.
DB01291
The risk or severity of hypokalemia can be increased when Fluocortolone is combined with Pirbuterol.
DB01363
The risk or severity of hypokalemia can be increased when Fluocortolone is combined with Ephedra sinica root.
DB01366
The risk or severity of hypokalemia can be increased when Fluocortolone is combined with Procaterol.
DB01407
The risk or severity of hypokalemia can be increased when Fluocortolone is combined with Clenbuterol.
DB04846
The risk or severity of hypokalemia can be increased when Fluocortolone is combined with Celiprolol.
DB05039
The risk or severity of hypokalemia can be increased when Fluocortolone is combined with Indacaterol.
DB06262
The risk or severity of hypokalemia can be increased when Fluocortolone is combined with Droxidopa.
DB06814
The risk or severity of hypokalemia can be increased when Fluocortolone is combined with Protokylol.
DB08957
The risk or severity of hypokalemia can be increased when Fluocortolone is combined with Hexoprenaline.
DB09080
The risk or severity of hypokalemia can be increased when Fluocortolone is combined with Olodaterol.
DB09273
The risk or severity of hypokalemia can be increased when Fluocortolone is combined with Doxofylline.
DB11124
The risk or severity of hypokalemia can be increased when Fluocortolone is combined with Racepinephrine.
DB11587
The risk or severity of hypokalemia can be increased when Fluocortolone is combined with Etafedrine.
DB11871
The risk or severity of hypokalemia can be increased when Fluocortolone is combined with PF-00610355.
DB12100
The risk or severity of hypokalemia can be increased when Fluocortolone is combined with Abediterol.
DB12526
The risk or severity of hypokalemia can be increased when Fluocortolone is combined with Batefenterol.
DB13139
The risk or severity of hypokalemia can be increased when Fluocortolone is combined with Levosalbutamol.
DB00834
The therapeutic efficacy of Mifepristone can be decreased when used in combination with Fluocortolone.
DB00648
The serum concentration of Fluocortolone can be decreased when it is combined with Mitotane.
DB00266
Fluocortolone may increase the anticoagulant activities of Dicoumarol.
DB00498
Fluocortolone may increase the anticoagulant activities of Phenindione.
DB00682
Fluocortolone may increase the anticoagulant activities of Warfarin.
DB00946
Fluocortolone may increase the anticoagulant activities of Phenprocoumon.
DB01418
Fluocortolone may increase the anticoagulant activities of Acenocoumarol.
DB03410
Fluocortolone may increase the anticoagulant activities of 4-hydroxycoumarin.
DB04665
Fluocortolone may increase the anticoagulant activities of Coumarin.
DB08496
Fluocortolone may increase the anticoagulant activities of (R)-warfarin.
DB08794
Fluocortolone may increase the anticoagulant activities of Ethyl biscoumacetate.
DB13136
Fluocortolone may increase the anticoagulant activities of Fluindione.
DB13275
Fluocortolone may increase the anticoagulant activities of Clorindione.
DB13347
Fluocortolone may increase the anticoagulant activities of Diphenadione.
DB13451
Fluocortolone may increase the anticoagulant activities of Tioclomarol.
DB14055
Fluocortolone may increase the anticoagulant activities of (S)-Warfarin.
DB01015
The risk or severity of myelosuppression can be increased when Fluocortolone is combined with Sulfamethoxazole.
DB01097
The risk or severity of adverse effects can be increased when Leflunomide is combined with Fluocortolone.
DB08895
Tofacitinib may increase the immunosuppressive activities of Fluocortolone.
DB00072
Trastuzumab may increase the neutropenic activities of Fluocortolone.
DB08868
Fingolimod may increase the immunosuppressive activities of Fluocortolone.
DB09220
The risk or severity of ulceration can be increased when Fluocortolone is combined with Nicorandil.
DB00864
Tacrolimus may increase the immunosuppressive activities of Fluocortolone.
DB00136
The therapeutic efficacy of Calcitriol can be decreased when used in combination with Fluocortolone.
DB00146
The therapeutic efficacy of Calcifediol can be decreased when used in combination with Fluocortolone.
DB00153
The therapeutic efficacy of Ergocalciferol can be decreased when used in combination with Fluocortolone.
DB00169
The therapeutic efficacy of Cholecalciferol can be decreased when used in combination with Fluocortolone.
DB00910
The therapeutic efficacy of Paricalcitol can be decreased when used in combination with Fluocortolone.
DB01070
The therapeutic efficacy of Dihydrotachysterol can be decreased when used in combination with Fluocortolone.
DB01436
The therapeutic efficacy of Alfacalcidol can be decreased when used in combination with Fluocortolone.
DB04258
The therapeutic efficacy of Seocalcitol can be decreased when used in combination with Fluocortolone.
DB04796
The therapeutic efficacy of Inecalcitol can be decreased when used in combination with Fluocortolone.
DB04891
The therapeutic efficacy of Becocalcidiol can be decreased when used in combination with Fluocortolone.
DB05295
The therapeutic efficacy of Eldecalcitol can be decreased when used in combination with Fluocortolone.
DB06117
The therapeutic efficacy of 1alpha,24S-Dihydroxyvitamin D2 can be decreased when used in combination with Fluocortolone.
DB06194
The therapeutic efficacy of Elocalcitol can be decreased when used in combination with Fluocortolone.
DB06272
The therapeutic efficacy of Maxacalcitol can be decreased when used in combination with Fluocortolone.
DB06410
The therapeutic efficacy of Doxercalciferol can be decreased when used in combination with Fluocortolone.
DB11094
The therapeutic efficacy of Vitamin D can be decreased when used in combination with Fluocortolone.
DB13097
The therapeutic efficacy of 1alpha-Hydroxyvitamin D5 can be decreased when used in combination with Fluocortolone.
DB12025
The serum concentration of Triptolide can be increased when it is combined with Fluocortolone.
DB00255
The serum concentration of Fluocortolone can be increased when it is combined with Diethylstilbestrol.
DB00294
The serum concentration of Fluocortolone can be increased when it is combined with Etonogestrel.
DB00304
The serum concentration of Fluocortolone can be increased when it is combined with Desogestrel.
DB00351
The serum concentration of Fluocortolone can be increased when it is combined with Megestrol acetate.
DB00367
The serum concentration of Fluocortolone can be increased when it is combined with Levonorgestrel.
DB00396
The serum concentration of Fluocortolone can be increased when it is combined with Progesterone.
DB00603
The serum concentration of Fluocortolone can be increased when it is combined with Medroxyprogesterone acetate.
DB00717
The serum concentration of Fluocortolone can be increased when it is combined with Norethisterone.
DB00783
The serum concentration of Fluocortolone can be increased when it is combined with Estradiol.
DB00823
The serum concentration of Fluocortolone can be increased when it is combined with Ethynodiol diacetate.
DB00957
The serum concentration of Fluocortolone can be increased when it is combined with Norgestimate.
DB00977
The serum concentration of Fluocortolone can be increased when it is combined with Ethinylestradiol.
DB01357
The serum concentration of Fluocortolone can be increased when it is combined with Mestranol.
DB01395
The serum concentration of Fluocortolone can be increased when it is combined with Drospirenone.
DB04066
The serum concentration of Fluocortolone can be increased when it is combined with p-Coumaric acid.
DB04574
The serum concentration of Fluocortolone can be increased when it is combined with Estrone sulfate.
DB04682
The serum concentration of Fluocortolone can be increased when it is combined with Octylphenoxy polyethoxyethanol.
DB04839
The serum concentration of Fluocortolone can be increased when it is combined with Cyproterone acetate.
DB05830
The serum concentration of Fluocortolone can be increased when it is combined with Trestolone.
DB06266
The serum concentration of Fluocortolone can be increased when it is combined with Lonidamine.
DB06713
The serum concentration of Fluocortolone can be increased when it is combined with Norelgestromin.
DB06730
The serum concentration of Fluocortolone can be increased when it is combined with Gestodene.
DB06789
The serum concentration of Fluocortolone can be increased when it is combined with Hydroxyprogesterone caproate.
DB08867
The serum concentration of Fluocortolone can be increased when it is combined with Ulipristal.
DB09123
The serum concentration of Fluocortolone can be increased when it is combined with Dienogest.
DB09371
The serum concentration of Fluocortolone can be increased when it is combined with Norethynodrel.
DB09389
The serum concentration of Fluocortolone can be increased when it is combined with Norgestrel.
DB09401
The serum concentration of Fluocortolone can be increased when it is combined with Isosorbide.
DB11507
The serum concentration of Fluocortolone can be increased when it is combined with Cloprostenol.
DB11619
The serum concentration of Fluocortolone can be increased when it is combined with Gestrinone.
DB11636
The serum concentration of Fluocortolone can be increased when it is combined with Nomegestrol.
DB12474
The serum concentration of Fluocortolone can be increased when it is combined with Lynestrenol.
DB13044
The serum concentration of Fluocortolone can be increased when it is combined with Gossypol.
DB13310
The serum concentration of Fluocortolone can be increased when it is combined with Ormeloxifene.
DB13528
The serum concentration of Fluocortolone can be increased when it is combined with Chlormadinone.
DB13563
The serum concentration of Fluocortolone can be increased when it is combined with Norgestrienone.
DB13685
The serum concentration of Fluocortolone can be increased when it is combined with Quingestanol.
DB13857
The serum concentration of Fluocortolone can be increased when it is combined with Demegestone.
DB13866
The serum concentration of Fluocortolone can be increased when it is combined with Etynodiol.
DB13944
The serum concentration of Fluocortolone can be increased when it is combined with Testosterone enanthate.
DB13953
The serum concentration of Fluocortolone can be increased when it is combined with Estradiol benzoate.
DB13954
The serum concentration of Fluocortolone can be increased when it is combined with Estradiol cypionate.
DB13956
The serum concentration of Fluocortolone can be increased when it is combined with Estradiol valerate.
DB13981
The serum concentration of Fluocortolone can be increased when it is combined with Nomegestrol acetate.
DB14678
The serum concentration of Fluocortolone can be increased when it is combined with Norethindrone enanthate.
DB00218
The risk or severity of tendinopathy can be increased when Fluocortolone is combined with Moxifloxacin.
DB00365
The risk or severity of tendinopathy can be increased when Fluocortolone is combined with Grepafloxacin.
DB00467
The risk or severity of tendinopathy can be increased when Fluocortolone is combined with Enoxacin.
DB00487
The risk or severity of tendinopathy can be increased when Fluocortolone is combined with Pefloxacin.
DB00537
The risk or severity of tendinopathy can be increased when Fluocortolone is combined with Ciprofloxacin.
DB00685
The risk or severity of tendinopathy can be increased when Fluocortolone is combined with Trovafloxacin.
DB00779
The risk or severity of tendinopathy can be increased when Fluocortolone is combined with Nalidixic acid.
DB00817
The risk or severity of tendinopathy can be increased when Fluocortolone is combined with Rosoxacin.
DB00827
The risk or severity of tendinopathy can be increased when Fluocortolone is combined with Cinoxacin.
DB00978
The risk or severity of tendinopathy can be increased when Fluocortolone is combined with Lomefloxacin.
DB01044
The risk or severity of tendinopathy can be increased when Fluocortolone is combined with Gatifloxacin.
DB01059
The risk or severity of tendinopathy can be increased when Fluocortolone is combined with Norfloxacin.
DB01137
The risk or severity of tendinopathy can be increased when Fluocortolone is combined with Levofloxacin.
DB01155
The risk or severity of tendinopathy can be increased when Fluocortolone is combined with Gemifloxacin.
DB01165
The risk or severity of tendinopathy can be increased when Fluocortolone is combined with Ofloxacin.
DB01208
The risk or severity of tendinopathy can be increased when Fluocortolone is combined with Sparfloxacin.
DB01405
The risk or severity of tendinopathy can be increased when Fluocortolone is combined with Temafloxacin.
DB04576
The risk or severity of tendinopathy can be increased when Fluocortolone is combined with Fleroxacin.
DB05488
The risk or severity of tendinopathy can be increased when Fluocortolone is combined with Technetium Tc-99m ciprofloxacin.
DB06160
The risk or severity of tendinopathy can be increased when Fluocortolone is combined with Garenoxacin.
DB06600
The risk or severity of tendinopathy can be increased when Fluocortolone is combined with Nemonoxacin.
DB08972
The risk or severity of tendinopathy can be increased when Fluocortolone is combined with Flumequine.
DB11404
The risk or severity of tendinopathy can be increased when Fluocortolone is combined with Enrofloxacin.
DB11443
The risk or severity of tendinopathy can be increased when Fluocortolone is combined with Orbifloxacin.
DB11491
The risk or severity of tendinopathy can be increased when Fluocortolone is combined with Sarafloxacin.
DB11511
The risk or severity of tendinopathy can be increased when Fluocortolone is combined with Difloxacin.
DB11774
The risk or severity of tendinopathy can be increased when Fluocortolone is combined with Pazufloxacin.
DB11892
The risk or severity of tendinopathy can be increased when Fluocortolone is combined with Prulifloxacin.
DB11943
The risk or severity of tendinopathy can be increased when Fluocortolone is combined with Delafloxacin.
DB13261
The risk or severity of tendinopathy can be increased when Fluocortolone is combined with Sitafloxacin.
DB13627
The risk or severity of tendinopathy can be increased when Fluocortolone is combined with Oxolinic acid.
DB13772
The risk or severity of tendinopathy can be increased when Fluocortolone is combined with Rufloxacin.
DB13823
The risk or severity of tendinopathy can be increased when Fluocortolone is combined with Pipemidic acid.
DB00310
Fluocortolone may increase the hypokalemic activities of Chlorthalidone.
DB00524
Fluocortolone may increase the hypokalemic activities of Metolazone.
DB00808
Fluocortolone may increase the hypokalemic activities of Indapamide.
DB01325
Fluocortolone may increase the hypokalemic activities of Quinethazone.
DB13989
Fluocortolone may increase the hypokalemic activities of Epitizide.
DB00621
The risk or severity of fluid retention can be increased when Fluocortolone is combined with Oxandrolone.
DB01185
The risk or severity of fluid retention can be increased when Fluocortolone is combined with Fluoxymesterone.
DB01406
The risk or severity of fluid retention can be increased when Fluocortolone is combined with Danazol.
DB06412
The risk or severity of fluid retention can be increased when Fluocortolone is combined with Oxymetholone.
DB06718
The risk or severity of fluid retention can be increased when Fluocortolone is combined with Stanozolol.
DB12461
The risk or severity of fluid retention can be increased when Fluocortolone is combined with GLPG-0492.
DB01377
The bioavailability of Fluocortolone can be decreased when combined with Magnesium oxide.
DB01390
The bioavailability of Fluocortolone can be decreased when combined with Sodium bicarbonate.
DB06723
The bioavailability of Fluocortolone can be decreased when combined with Aluminum hydroxide.
DB06724
The bioavailability of Fluocortolone can be decreased when combined with Calcium carbonate.
DB08938
The bioavailability of Fluocortolone can be decreased when combined with Magaldrate.
DB09104
The bioavailability of Fluocortolone can be decreased when combined with Magnesium hydroxide.
DB09281
The bioavailability of Fluocortolone can be decreased when combined with Magnesium trisilicate.
DB09481
The bioavailability of Fluocortolone can be decreased when combined with Magnesium carbonate.
DB13249
The bioavailability of Fluocortolone can be decreased when combined with Magnesium silicate.
DB13280
The bioavailability of Fluocortolone can be decreased when combined with Aluminium acetoacetate.
DB13322
The bioavailability of Fluocortolone can be decreased when combined with Hydrotalcite.
DB13486
The bioavailability of Fluocortolone can be decreased when combined with Magnesium peroxide.
DB13595
The bioavailability of Fluocortolone can be decreased when combined with Almasilate.
DB13626
The bioavailability of Fluocortolone can be decreased when combined with Aluminium glycinate.
DB13650
The bioavailability of Fluocortolone can be decreased when combined with Aloglutamol.
DB13829
The bioavailability of Fluocortolone can be decreased when combined with Calcium silicate.
DB14517
The bioavailability of Fluocortolone can be decreased when combined with Aluminium phosphate.
DB00214
The risk or severity of hypokalemia can be increased when Fluocortolone is combined with Torasemide.
DB00695
The risk or severity of hypokalemia can be increased when Fluocortolone is combined with Furosemide.
DB00887
The risk or severity of hypokalemia can be increased when Fluocortolone is combined with Bumetanide.
DB00903
The risk or severity of hypokalemia can be increased when Fluocortolone is combined with Etacrynic acid.
DB02925
The risk or severity of hypokalemia can be increased when Fluocortolone is combined with Piretanide.
DB08961
The risk or severity of hypokalemia can be increased when Fluocortolone is combined with Azosemide.
DB00328
The risk or severity of gastrointestinal irritation can be increased when Indomethacin is combined with Fluocortolone.
DB00795
The risk or severity of gastrointestinal irritation can be increased when Sulfasalazine is combined with Fluocortolone.
DB11466
The risk or severity of gastrointestinal irritation can be increased when Fluocortolone is combined with Tepoxalin.
DB00159
The risk or severity of gastrointestinal irritation can be increased when Fluocortolone is combined with Icosapent.
DB00244
The risk or severity of gastrointestinal irritation can be increased when Fluocortolone is combined with Mesalazine.
DB00461
The risk or severity of gastrointestinal irritation can be increased when Fluocortolone is combined with Nabumetone.
DB00465
The risk or severity of gastrointestinal irritation can be increased when Fluocortolone is combined with Ketorolac.
DB00469
The risk or severity of gastrointestinal irritation can be increased when Fluocortolone is combined with Tenoxicam.
DB00482
The risk or severity of gastrointestinal irritation can be increased when Fluocortolone is combined with Celecoxib.
DB00500
The risk or severity of gastrointestinal irritation can be increased when Fluocortolone is combined with Tolmetin.
DB00533
The risk or severity of gastrointestinal irritation can be increased when Fluocortolone is combined with Rofecoxib.
DB00554
The risk or severity of gastrointestinal irritation can be increased when Fluocortolone is combined with Piroxicam.
DB00573
The risk or severity of gastrointestinal irritation can be increased when Fluocortolone is combined with Fenoprofen.
DB00580
The risk or severity of gastrointestinal irritation can be increased when Fluocortolone is combined with Valdecoxib.
DB00586
The risk or severity of gastrointestinal irritation can be increased when Fluocortolone is combined with Diclofenac.
DB00605
The risk or severity of gastrointestinal irritation can be increased when Fluocortolone is combined with Sulindac.
DB00712
The risk or severity of gastrointestinal irritation can be increased when Fluocortolone is combined with Flurbiprofen.
DB00749
The risk or severity of gastrointestinal irritation can be increased when Fluocortolone is combined with Etodolac.
DB00784
The risk or severity of gastrointestinal irritation can be increased when Fluocortolone is combined with Mefenamic acid.
DB00788
The risk or severity of gastrointestinal irritation can be increased when Fluocortolone is combined with Naproxen.
DB00812
The risk or severity of gastrointestinal irritation can be increased when Fluocortolone is combined with Phenylbutazone.
DB00814
The risk or severity of gastrointestinal irritation can be increased when Fluocortolone is combined with Meloxicam.
DB00821
The risk or severity of gastrointestinal irritation can be increased when Fluocortolone is combined with Carprofen.
DB00861
The risk or severity of gastrointestinal irritation can be increased when Fluocortolone is combined with Diflunisal.
DB00936
The risk or severity of gastrointestinal irritation can be increased when Fluocortolone is combined with Salicylic acid.
DB00939
The risk or severity of gastrointestinal irritation can be increased when Fluocortolone is combined with Meclofenamic acid.
DB00991
The risk or severity of gastrointestinal irritation can be increased when Fluocortolone is combined with Oxaprozin.
DB01009
The risk or severity of gastrointestinal irritation can be increased when Fluocortolone is combined with Ketoprofen.
DB01014
The risk or severity of gastrointestinal irritation can be increased when Fluocortolone is combined with Balsalazide.
DB01050
The risk or severity of gastrointestinal irritation can be increased when Fluocortolone is combined with Ibuprofen.
DB01250
The risk or severity of gastrointestinal irritation can be increased when Fluocortolone is combined with Olsalazine.
DB01283
The risk or severity of gastrointestinal irritation can be increased when Fluocortolone is combined with Lumiracoxib.
DB01397
The risk or severity of gastrointestinal irritation can be increased when Fluocortolone is combined with Magnesium salicylate.
DB01399
The risk or severity of gastrointestinal irritation can be increased when Fluocortolone is combined with Salsalate.
DB01401
The risk or severity of gastrointestinal irritation can be increased when Fluocortolone is combined with Choline magnesium trisalicylate.
DB01419
The risk or severity of gastrointestinal irritation can be increased when Fluocortolone is combined with Antrafenine.
DB01424
The risk or severity of gastrointestinal irritation can be increased when Fluocortolone is combined with Aminophenazone.
DB01435
The risk or severity of gastrointestinal irritation can be increased when Fluocortolone is combined with Antipyrine.
DB01600
The risk or severity of gastrointestinal irritation can be increased when Fluocortolone is combined with Tiaprofenic acid.
DB01628
The risk or severity of gastrointestinal irritation can be increased when Fluocortolone is combined with Etoricoxib.
DB02224
The risk or severity of gastrointestinal irritation can be increased when Fluocortolone is combined with Taxifolin.
DB03585
The risk or severity of gastrointestinal irritation can be increased when Fluocortolone is combined with Oxyphenbutazone.
DB04725
The risk or severity of gastrointestinal irritation can be increased when Fluocortolone is combined with Licofelone.
DB04743
The risk or severity of gastrointestinal irritation can be increased when Fluocortolone is combined with Nimesulide.
DB04812
The risk or severity of gastrointestinal irritation can be increased when Fluocortolone is combined with Benoxaprofen.
DB04817
The risk or severity of gastrointestinal irritation can be increased when Fluocortolone is combined with Metamizole.
DB04828
The risk or severity of gastrointestinal irritation can be increased when Fluocortolone is combined with Zomepirac.
DB05095
The risk or severity of gastrointestinal irritation can be increased when Fluocortolone is combined with Cimicoxib.
DB06725
The risk or severity of gastrointestinal irritation can be increased when Fluocortolone is combined with Lornoxicam.
DB06736
The risk or severity of gastrointestinal irritation can be increased when Fluocortolone is combined with Aceclofenac.
DB06737
The risk or severity of gastrointestinal irritation can be increased when Fluocortolone is combined with Zaltoprofen.
DB07402
The risk or severity of gastrointestinal irritation can be increased when Fluocortolone is combined with Azapropazone.
DB08439
The risk or severity of gastrointestinal irritation can be increased when Fluocortolone is combined with Parecoxib.
DB08797
The risk or severity of gastrointestinal irritation can be increased when Fluocortolone is combined with Salicylamide.
DB08940
The risk or severity of gastrointestinal irritation can be increased when Fluocortolone is combined with Kebuzone.
DB08942
The risk or severity of gastrointestinal irritation can be increased when Fluocortolone is combined with Isoxicam.
DB08951
The risk or severity of gastrointestinal irritation can be increased when Fluocortolone is combined with Indoprofen.
DB08955
The risk or severity of gastrointestinal irritation can be increased when Fluocortolone is combined with Ibuproxam.
DB08976
The risk or severity of gastrointestinal irritation can be increased when Fluocortolone is combined with Floctafenine.
DB08981
The risk or severity of gastrointestinal irritation can be increased when Fluocortolone is combined with Fenbufen.
DB08984
The risk or severity of gastrointestinal irritation can be increased when Fluocortolone is combined with Etofenamate.
DB08991
The risk or severity of gastrointestinal irritation can be increased when Fluocortolone is combined with Epirizole.
DB09084
The risk or severity of gastrointestinal irritation can be increased when Fluocortolone is combined with Benzydamine.
DB09212
The risk or severity of gastrointestinal irritation can be increased when Fluocortolone is combined with Loxoprofen.
DB09213
The risk or severity of gastrointestinal irritation can be increased when Fluocortolone is combined with Dexibuprofen.
DB09214
The risk or severity of gastrointestinal irritation can be increased when Fluocortolone is combined with Dexketoprofen.
DB09215
The risk or severity of gastrointestinal irritation can be increased when Fluocortolone is combined with Droxicam.
DB09216
The risk or severity of gastrointestinal irritation can be increased when Fluocortolone is combined with Tolfenamic acid.
DB09217
The risk or severity of gastrointestinal irritation can be increased when Fluocortolone is combined with Firocoxib.
DB09218
The risk or severity of gastrointestinal irritation can be increased when Fluocortolone is combined with Clonixin.
DB09285
The risk or severity of gastrointestinal irritation can be increased when Fluocortolone is combined with Morniflumate.
DB09288
The risk or severity of gastrointestinal irritation can be increased when Fluocortolone is combined with Propacetamol.
DB09295
The risk or severity of gastrointestinal irritation can be increased when Fluocortolone is combined with Talniflumate.
DB11455
The risk or severity of gastrointestinal irritation can be increased when Fluocortolone is combined with Robenacoxib.
DB11518
The risk or severity of gastrointestinal irritation can be increased when Fluocortolone is combined with Flunixin.
DB12399
The risk or severity of gastrointestinal irritation can be increased when Fluocortolone is combined with Polmacoxib.
DB12445
The risk or severity of gastrointestinal irritation can be increased when Fluocortolone is combined with Nitroaspirin.
DB12545
The risk or severity of gastrointestinal irritation can be increased when Fluocortolone is combined with Indobufen.
DB12610
The risk or severity of gastrointestinal irritation can be increased when Fluocortolone is combined with Ebselen.
DB13001
The risk or severity of gastrointestinal irritation can be increased when Fluocortolone is combined with Tinoridine.
DB13167
The risk or severity of gastrointestinal irritation can be increased when Fluocortolone is combined with Alclofenac.
DB13217
The risk or severity of gastrointestinal irritation can be increased when Fluocortolone is combined with Fentiazac.
DB13232
The risk or severity of gastrointestinal irritation can be increased when Fluocortolone is combined with Suxibuzone.
DB13286
The risk or severity of gastrointestinal irritation can be increased when Fluocortolone is combined with Bumadizone.
DB13314
The risk or severity of gastrointestinal irritation can be increased when Fluocortolone is combined with Alminoprofen.
DB13371
The risk or severity of gastrointestinal irritation can be increased when Fluocortolone is combined with Difenpiramide.
DB13407
The risk or severity of gastrointestinal irritation can be increased when Fluocortolone is combined with Nifenazone.
DB13432
The risk or severity of gastrointestinal irritation can be increased when Fluocortolone is combined with Lonazolac.
DB13481
The risk or severity of gastrointestinal irritation can be increased when Fluocortolone is combined with Tenidap.
DB13524
The risk or severity of gastrointestinal irritation can be increased when Fluocortolone is combined with Propyphenazone.
DB13527
The risk or severity of gastrointestinal irritation can be increased when Fluocortolone is combined with Proglumetacin.
DB13538
The risk or severity of gastrointestinal irritation can be increased when Fluocortolone is combined with Guacetisal.
DB13544
The risk or severity of gastrointestinal irritation can be increased when Fluocortolone is combined with Ethenzamide.
DB13612
The risk or severity of gastrointestinal irritation can be increased when Fluocortolone is combined with Carbaspirin calcium.
DB13629
The risk or severity of gastrointestinal irritation can be increased when Fluocortolone is combined with Mofebutazone.
DB13649
The risk or severity of gastrointestinal irritation can be increased when Fluocortolone is combined with Proquazone.
DB13657
The risk or severity of gastrointestinal irritation can be increased when Fluocortolone is combined with Benorilate.
DB13722
The risk or severity of gastrointestinal irritation can be increased when Fluocortolone is combined with Pirprofen.
DB13783
The risk or severity of gastrointestinal irritation can be increased when Fluocortolone is combined with Acemetacin.
DB13860
The risk or severity of gastrointestinal irritation can be increased when Fluocortolone is combined with Imidazole salicylate.
DB14059
The risk or severity of gastrointestinal irritation can be increased when Fluocortolone is combined with SC-236.
DB14060
The risk or severity of gastrointestinal irritation can be increased when Fluocortolone is combined with NS-398.
DB14938
The risk or severity of gastrointestinal irritation can be increased when Fluocortolone is combined with Flurbiprofen axetil.
DB00515
The therapeutic efficacy of Fluocortolone can be decreased when used in combination with Cisplatin.
DB00888
The therapeutic efficacy of Fluocortolone can be decreased when used in combination with Mechlorethamine.
DB04572
The therapeutic efficacy of Fluocortolone can be decreased when used in combination with Thiotepa.
DB00871
The therapeutic efficacy of Terbutaline can be decreased when used in combination with Fluocortolone.
DB01408
The therapeutic efficacy of Bambuterol can be decreased when used in combination with Fluocortolone.
DB00082
The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Fluocortolone.
DB00358
The therapeutic efficacy of Mefloquine can be decreased when used in combination with Fluocortolone.
DB00382
The therapeutic efficacy of Tacrine can be decreased when used in combination with Fluocortolone.
DB00391
The therapeutic efficacy of Sulpiride can be decreased when used in combination with Fluocortolone.
DB00392
The therapeutic efficacy of Profenamine can be decreased when used in combination with Fluocortolone.
DB00477
The therapeutic efficacy of Chlorpromazine can be decreased when used in combination with Fluocortolone.
DB00483
The therapeutic efficacy of Gallamine triethiodide can be decreased when used in combination with Fluocortolone.
DB00508
The therapeutic efficacy of Triflupromazine can be decreased when used in combination with Fluocortolone.
DB00527
The therapeutic efficacy of Cinchocaine can be decreased when used in combination with Fluocortolone.
DB00545
The therapeutic efficacy of Pyridostigmine can be decreased when used in combination with Fluocortolone.
DB00585
The therapeutic efficacy of Nizatidine can be decreased when used in combination with Fluocortolone.
DB00674
The therapeutic efficacy of Galantamine can be decreased when used in combination with Fluocortolone.
DB00677
The therapeutic efficacy of Isoflurophate can be decreased when used in combination with Fluocortolone.
DB00711
The therapeutic efficacy of Diethylcarbamazine can be decreased when used in combination with Fluocortolone.
DB00721
The therapeutic efficacy of Procaine can be decreased when used in combination with Fluocortolone.
DB00805
The therapeutic efficacy of Minaprine can be decreased when used in combination with Fluocortolone.
DB00843
The therapeutic efficacy of Donepezil can be decreased when used in combination with Fluocortolone.
DB00941
The therapeutic efficacy of Hexafluronium can be decreased when used in combination with Fluocortolone.
DB00944
The therapeutic efficacy of Demecarium can be decreased when used in combination with Fluocortolone.
DB00981
The therapeutic efficacy of Physostigmine can be decreased when used in combination with Fluocortolone.
DB00989
The therapeutic efficacy of Rivastigmine can be decreased when used in combination with Fluocortolone.
DB01010
The therapeutic efficacy of Edrophonium can be decreased when used in combination with Fluocortolone.
DB01035
The therapeutic efficacy of Procainamide can be decreased when used in combination with Fluocortolone.
DB01043
The therapeutic efficacy of Memantine can be decreased when used in combination with Fluocortolone.
DB01122
The therapeutic efficacy of Ambenonium can be decreased when used in combination with Fluocortolone.
DB01199
The therapeutic efficacy of Tubocurarine can be decreased when used in combination with Fluocortolone.
DB01221
The therapeutic efficacy of Ketamine can be decreased when used in combination with Fluocortolone.
DB01233
The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Fluocortolone.
DB01245
The therapeutic efficacy of Decamethonium can be decreased when used in combination with Fluocortolone.
DB01337
The therapeutic efficacy of Pancuronium can be decreased when used in combination with Fluocortolone.
DB01338
The therapeutic efficacy of Pipecuronium can be decreased when used in combination with Fluocortolone.
DB01381
The therapeutic efficacy of Ginkgo biloba can be decreased when used in combination with Fluocortolone.
DB01400
The therapeutic efficacy of Neostigmine can be decreased when used in combination with Fluocortolone.
DB02365
The therapeutic efficacy of 1,10-Phenanthroline can be decreased when used in combination with Fluocortolone.
DB02845
The therapeutic efficacy of Methylphosphinic Acid can be decreased when used in combination with Fluocortolone.
DB04864
The therapeutic efficacy of Huperzine A can be decreased when used in combination with Fluocortolone.
DB04892
The therapeutic efficacy of Phenserine can be decreased when used in combination with Fluocortolone.
DB05386
The therapeutic efficacy of Regramostim can be decreased when used in combination with Fluocortolone.
DB06692
The therapeutic efficacy of Aprotinin can be decreased when used in combination with Fluocortolone.
DB06756
The therapeutic efficacy of Glycine betaine can be decreased when used in combination with Fluocortolone.
DB06774
The therapeutic efficacy of Capsaicin can be decreased when used in combination with Fluocortolone.
DB11390
The therapeutic efficacy of Coumaphos can be decreased when used in combination with Fluocortolone.
DB11397
The therapeutic efficacy of Dichlorvos can be decreased when used in combination with Fluocortolone.
DB11412
The therapeutic efficacy of Fenthion can be decreased when used in combination with Fluocortolone.
DB11473
The therapeutic efficacy of Metrifonate can be decreased when used in combination with Fluocortolone.
DB12482
The therapeutic efficacy of Acotiamide can be decreased when used in combination with Fluocortolone.
DB13058
The therapeutic efficacy of Methanesulfonyl Fluoride can be decreased when used in combination with Fluocortolone.
DB13495
The therapeutic efficacy of Paraoxon can be decreased when used in combination with Fluocortolone.
DB13503
The therapeutic efficacy of Tyrothricin can be decreased when used in combination with Fluocortolone.
DB13668
The therapeutic efficacy of Ipidacrine can be decreased when used in combination with Fluocortolone.
DB13694
The therapeutic efficacy of Distigmine can be decreased when used in combination with Fluocortolone.
DB14031
The therapeutic efficacy of Tretamine can be decreased when used in combination with Fluocortolone.
DB15317
The therapeutic efficacy of Posiphen can be decreased when used in combination with Fluocortolone.
DB00202
The risk or severity of myopathy and weakness can be increased when Succinylcholine is combined with Fluocortolone.
DB00416
The risk or severity of myopathy and weakness can be increased when Metocurine iodide is combined with Fluocortolone.
DB00565
The risk or severity of myopathy and weakness can be increased when Cisatracurium is combined with Fluocortolone.
DB00728
The risk or severity of myopathy and weakness can be increased when Rocuronium is combined with Fluocortolone.
DB00732
The risk or severity of myopathy and weakness can be increased when Atracurium besylate is combined with Fluocortolone.
DB01135
The risk or severity of myopathy and weakness can be increased when Doxacurium is combined with Fluocortolone.
DB01226
The risk or severity of myopathy and weakness can be increased when Mivacurium is combined with Fluocortolone.
DB01336
The risk or severity of myopathy and weakness can be increased when Metocurine is combined with Fluocortolone.
DB01339
The risk or severity of myopathy and weakness can be increased when Vecuronium is combined with Fluocortolone.
DB04834
The risk or severity of myopathy and weakness can be increased when Rapacuronium is combined with Fluocortolone.
DB11156
The risk or severity of myopathy and weakness can be increased when Pyrantel is combined with Fluocortolone.
DB12989
The risk or severity of myopathy and weakness can be increased when Neosaxitoxin is combined with Fluocortolone.
DB13295
The risk or severity of myopathy and weakness can be increased when Atracurium is combined with Fluocortolone.
DB13584
The risk or severity of myopathy and weakness can be increased when Gallamine is combined with Fluocortolone.
DB13648
The risk or severity of myopathy and weakness can be increased when Alcuronium is combined with Fluocortolone.
DB03793
The therapeutic efficacy of Benzoic acid can be decreased when used in combination with Fluocortolone.
DB06819
The therapeutic efficacy of Phenylbutyric acid can be decreased when used in combination with Fluocortolone.
DB08909
The therapeutic efficacy of Glycerol phenylbutyrate can be decreased when used in combination with Fluocortolone.
DB09269
The therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with Fluocortolone.
DB01108
The risk or severity of edema formation can be increased when Trilostane is combined with Fluocortolone.
DB00624
The risk or severity of edema formation can be increased when Fluocortolone is combined with Testosterone.
DB00984
The risk or severity of edema formation can be increased when Fluocortolone is combined with Nandrolone phenpropionate.
DB01420
The risk or severity of edema formation can be increased when Fluocortolone is combined with Testosterone propionate.
DB06710
The risk or severity of edema formation can be increased when Fluocortolone is combined with Methyltestosterone.
DB08804
The risk or severity of edema formation can be increased when Fluocortolone is combined with Nandrolone decanoate.
DB13169
The risk or severity of edema formation can be increased when Fluocortolone is combined with Nandrolone.
DB13587
The risk or severity of edema formation can be increased when Fluocortolone is combined with Mesterolone.
DB13943
The risk or severity of edema formation can be increased when Fluocortolone is combined with Testosterone cypionate.
DB13946
The risk or severity of edema formation can be increased when Fluocortolone is combined with Testosterone undecanoate.
DB01434
The risk or severity of edema formation can be increased when 19-norandrostenedione is combined with Fluocortolone.
DB01456
The risk or severity of edema formation can be increased when 5-androstenedione is combined with Fluocortolone.
DB01471
The risk or severity of edema formation can be increased when Bolasterone is combined with Fluocortolone.
DB01481
The risk or severity of edema formation can be increased when 1-Testosterone is combined with Fluocortolone.
DB01485
The risk or severity of edema formation can be increased when 4-Hydroxytestosterone is combined with Fluocortolone.
DB01521
The risk or severity of edema formation can be increased when Clostebol is combined with Fluocortolone.
DB01524
The risk or severity of edema formation can be increased when Androstenediol is combined with Fluocortolone.
DB01536
The risk or severity of edema formation can be increased when Androstenedione is combined with Fluocortolone.
DB01541
The risk or severity of edema formation can be increased when Boldenone is combined with Fluocortolone.
DB01554
The risk or severity of edema formation can be increased when Bolandiol is combined with Fluocortolone.
DB01564
The risk or severity of edema formation can be increased when Calusterone is combined with Fluocortolone.
DB05107
The risk or severity of edema formation can be increased when 16-Bromoepiandrosterone is combined with Fluocortolone.
DB05804
The risk or severity of edema formation can be increased when Prasterone sulfate is combined with Fluocortolone.
DB06250
The risk or severity of edema formation can be increased when Fluasterone is combined with Fluocortolone.
DB07768
The risk or severity of edema formation can be increased when Epitestosterone is combined with Fluocortolone.
DB08619
The risk or severity of edema formation can be increased when Testosterone succinate is combined with Fluocortolone.
DB08905
The risk or severity of edema formation can be increased when Formestane is combined with Fluocortolone.
DB11429
The risk or severity of edema formation can be increased when Mibolerone is combined with Fluocortolone.
DB12194
The risk or severity of edema formation can be increased when Atamestane is combined with Fluocortolone.
DB13710
The risk or severity of edema formation can be increased when Metenolone is combined with Fluocortolone.
DB13947
The risk or severity of edema formation can be increased when Testosterone enantate benzilic acid hydrazone is combined with Fluocortolone.
DB13958
The risk or severity of edema formation can be increased when Trestolone acetate is combined with Fluocortolone.
DB11642
The serum concentration of Fluocortolone can be decreased when it is combined with Pitolisant.
DB09046
The metabolism of Fluocortolone can be increased when combined with Metreleptin.
DB00186
The metabolism of Lorazepam can be increased when combined with Fluocortolone.
DB00191
The metabolism of Phentermine can be increased when combined with Fluocortolone.
DB00207
The metabolism of Azithromycin can be increased when combined with Fluocortolone.
DB00208
The metabolism of Ticlopidine can be increased when combined with Fluocortolone.
DB00246
The metabolism of Ziprasidone can be increased when combined with Fluocortolone.
DB00247
The metabolism of Methysergide can be increased when combined with Fluocortolone.
DB00264
The metabolism of Metoprolol can be increased when combined with Fluocortolone.
DB00426
The metabolism of Famciclovir can be increased when combined with Fluocortolone.
DB00433
The metabolism of Prochlorperazine can be increased when combined with Fluocortolone.
DB00454
The metabolism of Meperidine can be increased when combined with Fluocortolone.
DB00476
The metabolism of Duloxetine can be increased when combined with Fluocortolone.
DB00518
The metabolism of Albendazole can be increased when combined with Fluocortolone.
DB00549
The metabolism of Zafirlukast can be increased when combined with Fluocortolone.
DB00567
The metabolism of Cephalexin can be increased when combined with Fluocortolone.
DB00590
The metabolism of Doxazosin can be increased when combined with Fluocortolone.
DB01039
The metabolism of Fenofibrate can be increased when combined with Fluocortolone.
DB01072
The metabolism of Atazanavir can be increased when combined with Fluocortolone.
DB01098
The metabolism of Rosuvastatin can be increased when combined with Fluocortolone.
DB01323
The metabolism of St. John's Wort can be increased when combined with Fluocortolone.
DB01411
The metabolism of Pranlukast can be increased when combined with Fluocortolone.
DB01431
The metabolism of Allylestrenol can be increased when combined with Fluocortolone.
DB01624
The metabolism of Zuclopenthixol can be increased when combined with Fluocortolone.
DB06201
The metabolism of Rufinamide can be increased when combined with Fluocortolone.
DB06218
The metabolism of Lacosamide can be increased when combined with Fluocortolone.
DB06480
The metabolism of Prucalopride can be increased when combined with Fluocortolone.
DB06717
The metabolism of Fosaprepitant can be increased when combined with Fluocortolone.
DB09030
The metabolism of Vorapaxar can be increased when combined with Fluocortolone.
DB09034
The metabolism of Suvorexant can be increased when combined with Fluocortolone.
DB09048
The metabolism of Netupitant can be increased when combined with Fluocortolone.
DB09071
The metabolism of Tasimelteon can be increased when combined with Fluocortolone.
DB09079
The metabolism of Nintedanib can be increased when combined with Fluocortolone.
DB09299
The metabolism of Tenofovir alafenamide can be increased when combined with Fluocortolone.
DB11273
The metabolism of Dihydroergocornine can be increased when combined with Fluocortolone.
DB11730
The metabolism of Ribociclib can be increased when combined with Fluocortolone.
DB11742
The metabolism of Ebastine can be increased when combined with Fluocortolone.
DB11952
The metabolism of Duvelisib can be increased when combined with Fluocortolone.
DB12141
The metabolism of Gilteritinib can be increased when combined with Fluocortolone.
DB12515
The metabolism of 9-aminocamptothecin can be increased when combined with Fluocortolone.
DB12825
The metabolism of Lefamulin can be increased when combined with Fluocortolone.
DB12887
The metabolism of Tazemetostat can be increased when combined with Fluocortolone.
DB12952
The metabolism of Methylprednisone can be increased when combined with Fluocortolone.
DB13345
The metabolism of Dihydroergocristine can be increased when combined with Fluocortolone.
DB13385
The metabolism of Dihydroergocryptine can be increased when combined with Fluocortolone.
DB14009
The metabolism of Medical Cannabis can be increased when combined with Fluocortolone.
DB14126
The metabolism of Tenofovir can be increased when combined with Fluocortolone.
DB15444
The metabolism of Elexacaftor can be increased when combined with Fluocortolone.
DB00342
The metabolism of Terfenadine can be increased when combined with Fluocortolone.
DB00604
The metabolism of Cisapride can be increased when combined with Fluocortolone.
DB11633
The metabolism of Isavuconazole can be increased when combined with Fluocortolone.
DB00188
The metabolism of Fluocortolone can be increased when combined with Bortezomib.
DB00309
The metabolism of Fluocortolone can be increased when combined with Vindesine.
DB00361
The metabolism of Fluocortolone can be increased when combined with Vinorelbine.
DB00398
The metabolism of Fluocortolone can be increased when combined with Sorafenib.
DB00444
The metabolism of Fluocortolone can be increased when combined with Teniposide.
DB00531
The metabolism of Fluocortolone can be increased when combined with Cyclophosphamide.
DB00541
The metabolism of Fluocortolone can be increased when combined with Vincristine.
DB00563
The metabolism of Fluocortolone can be increased when combined with Methotrexate.
DB00564
The metabolism of Fluocortolone can be increased when combined with Carbamazepine.
DB00570
The metabolism of Fluocortolone can be increased when combined with Vinblastine.
DB00762
The metabolism of Fluocortolone can be increased when combined with Irinotecan.
DB00773
The metabolism of Fluocortolone can be increased when combined with Etoposide.
DB00877
The metabolism of Fluocortolone can be increased when combined with Sirolimus.
DB00997
The metabolism of Fluocortolone can be increased when combined with Doxorubicin.
DB01008
The metabolism of Fluocortolone can be increased when combined with Busulfan.
DB01181
The metabolism of Fluocortolone can be increased when combined with Ifosfamide.
DB01229
The metabolism of Fluocortolone can be increased when combined with Paclitaxel.
DB01248
The metabolism of Fluocortolone can be increased when combined with Docetaxel.
DB01254
The metabolism of Fluocortolone can be increased when combined with Dasatinib.
DB01590
The metabolism of Fluocortolone can be increased when combined with Everolimus.
DB04845
The metabolism of Fluocortolone can be increased when combined with Ixabepilone.
DB04868
The metabolism of Fluocortolone can be increased when combined with Nilotinib.
DB05109
The metabolism of Fluocortolone can be increased when combined with Trabectedin.
DB05773
The metabolism of Fluocortolone can be increased when combined with Trastuzumab emtansine.
DB06287
The metabolism of Fluocortolone can be increased when combined with Temsirolimus.
DB06589
The metabolism of Fluocortolone can be increased when combined with Pazopanib.
DB06603
The metabolism of Fluocortolone can be increased when combined with Panobinostat.
DB06616
The metabolism of Fluocortolone can be increased when combined with Bosutinib.
DB06772
The metabolism of Fluocortolone can be increased when combined with Cabazitaxel.
DB08870
The metabolism of Fluocortolone can be increased when combined with Brentuximab vedotin.
DB08877
The metabolism of Fluocortolone can be increased when combined with Ruxolitinib.
DB08901
The metabolism of Fluocortolone can be increased when combined with Ponatinib.
DB08910
The metabolism of Fluocortolone can be increased when combined with Pomalidomide.
DB09054
The metabolism of Idelalisib can be increased when combined with Fluocortolone.
DB09073
The metabolism of Palbociclib can be increased when combined with Fluocortolone.
DB09074
The metabolism of Olaparib can be increased when combined with Fluocortolone.
DB11817
The metabolism of Baricitinib can be increased when combined with Fluocortolone.
DB12371
The metabolism of Siponimod can be increased when combined with Fluocortolone.
DB00637
The metabolism of Astemizole can be increased when combined with Fluocortolone.
DB01100
The metabolism of Pimozide can be increased when combined with Fluocortolone.
DB01118
The metabolism of Amiodarone can be increased when combined with Fluocortolone.
DB05239
The metabolism of Cobimetinib can be increased when combined with Fluocortolone.
DB08827
The metabolism of Lomitapide can be increased when combined with Fluocortolone.
DB09330
The metabolism of Osimertinib can be increased when combined with Fluocortolone.
DB11963
The metabolism of Dacomitinib can be increased when combined with Fluocortolone.
DB12015
The metabolism of Alpelisib can be increased when combined with Fluocortolone.
DB00204
The metabolism of Dofetilide can be increased when combined with Fluocortolone.
DB00248
The metabolism of Cabergoline can be increased when combined with Fluocortolone.
DB00277
The metabolism of Theophylline can be increased when combined with Fluocortolone.
DB00530
The metabolism of Erlotinib can be increased when combined with Fluocortolone.
DB00675
The metabolism of Tamoxifen can be increased when combined with Fluocortolone.
DB00908
The metabolism of Quinidine can be increased when combined with Fluocortolone.
DB01223
The metabolism of Aminophylline can be increased when combined with Fluocortolone.
DB04855
The metabolism of Dronedarone can be increased when combined with Fluocortolone.
DB05294
The metabolism of Vandetanib can be increased when combined with Fluocortolone.
DB06595
The metabolism of Midostaurin can be increased when combined with Fluocortolone.
DB06626
The metabolism of Axitinib can be increased when combined with Fluocortolone.
DB08865
The metabolism of Crizotinib can be increased when combined with Fluocortolone.
DB08881
The metabolism of Vemurafenib can be increased when combined with Fluocortolone.
DB08912
The metabolism of Dabrafenib can be increased when combined with Fluocortolone.
DB09143
The metabolism of Sonidegib can be increased when combined with Fluocortolone.
DB09289
The metabolism of Tianeptine can be increased when combined with Fluocortolone.
DB09570
The metabolism of Ixazomib can be increased when combined with Fluocortolone.
DB11363
The metabolism of Alectinib can be increased when combined with Fluocortolone.
DB11581
The metabolism of Venetoclax can be increased when combined with Fluocortolone.
DB11641
The metabolism of Vinflunine can be increased when combined with Fluocortolone.
DB11703
The metabolism of Acalabrutinib can be increased when combined with Fluocortolone.
DB11828
The metabolism of Neratinib can be increased when combined with Fluocortolone.
DB12147
The metabolism of Erdafitinib can be increased when combined with Fluocortolone.
DB12267
The metabolism of Brigatinib can be increased when combined with Fluocortolone.
DB12483
The metabolism of Copanlisib can be increased when combined with Fluocortolone.
DB12978
The metabolism of Pexidartinib can be increased when combined with Fluocortolone.
DB13874
The metabolism of Enasidenib can be increased when combined with Fluocortolone.
DB14568
The metabolism of Ivosidenib can be increased when combined with Fluocortolone.
DB15035
The metabolism of Zanubrutinib can be increased when combined with Fluocortolone.
DB00575
The metabolism of Clonidine can be increased when combined with Fluocortolone.
DB06176
The metabolism of Romidepsin can be increased when combined with Fluocortolone.
DB06212
The metabolism of Tolvaptan can be increased when combined with Fluocortolone.
DB08896
The metabolism of Regorafenib can be increased when combined with Fluocortolone.
DB12001
The metabolism of Abemaciclib can be increased when combined with Fluocortolone.
DB00320
The metabolism of Dihydroergotamine can be increased when combined with Fluocortolone.
DB00696
The metabolism of Ergotamine can be increased when combined with Fluocortolone.
DB00872
The metabolism of Conivaptan can be increased when combined with Fluocortolone.
DB01128
The metabolism of Bicalutamide can be increased when combined with Fluocortolone.
DB01242
The metabolism of Clomipramine can be increased when combined with Fluocortolone.
DB00540
The metabolism of Nortriptyline can be increased when combined with Fluocortolone.
DB01227
The metabolism of Levacetylmethadol can be increased when combined with Fluocortolone.
DB00199
The metabolism of Erythromycin can be increased when combined with Fluocortolone.
DB00203
The metabolism of Sildenafil can be increased when combined with Fluocortolone.
DB00224
The metabolism of Indinavir can be increased when combined with Fluocortolone.
DB00227
The metabolism of Lovastatin can be increased when combined with Fluocortolone.
DB00238
The metabolism of Nevirapine can be increased when combined with Fluocortolone.
DB00250
The metabolism of Dapsone can be increased when combined with Fluocortolone.
DB00281
The metabolism of Lidocaine can be increased when combined with Fluocortolone.
DB00317
The metabolism of Gefitinib can be increased when combined with Fluocortolone.
DB00321
The metabolism of Amitriptyline can be increased when combined with Fluocortolone.
DB00333
The metabolism of Methadone can be increased when combined with Fluocortolone.
DB00343
The metabolism of Diltiazem can be increased when combined with Fluocortolone.
DB00401
The metabolism of Nisoldipine can be increased when combined with Fluocortolone.
DB00404
The metabolism of Alprazolam can be increased when combined with Fluocortolone.
DB00439
The metabolism of Cerivastatin can be increased when combined with Fluocortolone.
DB00490
The metabolism of Buspirone can be increased when combined with Fluocortolone.
DB00497
The metabolism of Oxycodone can be increased when combined with Fluocortolone.
DB00499
The metabolism of Flutamide can be increased when combined with Fluocortolone.
DB00514
The metabolism of Dextromethorphan can be increased when combined with Fluocortolone.
DB00528
The metabolism of Lercanidipine can be increased when combined with Fluocortolone.
DB00557
The metabolism of Hydroxyzine can be increased when combined with Fluocortolone.
DB00571
The metabolism of Propranolol can be increased when combined with Fluocortolone.
DB00608
The metabolism of Chloroquine can be increased when combined with Fluocortolone.
DB00641
The metabolism of Simvastatin can be increased when combined with Fluocortolone.
DB00655
The metabolism of Estrone can be increased when combined with Fluocortolone.
DB00656
The metabolism of Trazodone can be increased when combined with Fluocortolone.
DB00661
The metabolism of Verapamil can be increased when combined with Fluocortolone.
DB00673
The metabolism of Aprepitant can be increased when combined with Fluocortolone.
DB00683
The metabolism of Midazolam can be increased when combined with Fluocortolone.
DB00700
The metabolism of Eplerenone can be increased when combined with Fluocortolone.
DB00701
The metabolism of Amprenavir can be increased when combined with Fluocortolone.
DB00714
The metabolism of Apomorphine can be increased when combined with Fluocortolone.
DB00734
The metabolism of Risperidone can be increased when combined with Fluocortolone.
DB00741
The metabolism of Hydrocortisone can be increased when combined with Fluocortolone.
DB00758
The metabolism of Clopidogrel can be increased when combined with Fluocortolone.
DB00802
The metabolism of Alfentanil can be increased when combined with Fluocortolone.
DB00813
The metabolism of Fentanyl can be increased when combined with Fluocortolone.
DB00820
The metabolism of Tadalafil can be increased when combined with Fluocortolone.
DB00822
The metabolism of Disulfiram can be increased when combined with Fluocortolone.
DB00829
The metabolism of Diazepam can be increased when combined with Fluocortolone.
DB00862
The metabolism of Vardenafil can be increased when combined with Fluocortolone.
DB00897
The metabolism of Triazolam can be increased when combined with Fluocortolone.
DB00904
The metabolism of Ondansetron can be increased when combined with Fluocortolone.
DB00909
The metabolism of Zonisamide can be increased when combined with Fluocortolone.
DB00916
The metabolism of Metronidazole can be increased when combined with Fluocortolone.
DB00921
The metabolism of Buprenorphine can be increased when combined with Fluocortolone.
DB00962
The metabolism of Zaleplon can be increased when combined with Fluocortolone.
DB00972
The metabolism of Azelastine can be increased when combined with Fluocortolone.
DB00976
The metabolism of Telithromycin can be increased when combined with Fluocortolone.
DB01023
The metabolism of Felodipine can be increased when combined with Fluocortolone.
DB01054
The metabolism of Nitrendipine can be increased when combined with Fluocortolone.
DB01058
The metabolism of Praziquantel can be increased when combined with Fluocortolone.
DB01062
The metabolism of Oxybutynin can be increased when combined with Fluocortolone.
DB01076
The metabolism of Atorvastatin can be increased when combined with Fluocortolone.
DB01095
The metabolism of Fluvastatin can be increased when combined with Fluocortolone.
DB01103
The metabolism of Quinacrine can be increased when combined with Fluocortolone.
DB01114
The metabolism of Chlorpheniramine can be increased when combined with Fluocortolone.
DB01115
The metabolism of Nifedipine can be increased when combined with Fluocortolone.
DB01126
The metabolism of Dutasteride can be increased when combined with Fluocortolone.
DB01166
The metabolism of Cilostazol can be increased when combined with Fluocortolone.
DB01184
The metabolism of Domperidone can be increased when combined with Fluocortolone.
DB01190
The metabolism of Clindamycin can be increased when combined with Fluocortolone.
DB01211
The metabolism of Clarithromycin can be increased when combined with Fluocortolone.
DB01216
The metabolism of Finasteride can be increased when combined with Fluocortolone.
DB01218
The metabolism of Halofantrine can be increased when combined with Fluocortolone.
DB01224
The metabolism of Quetiapine can be increased when combined with Fluocortolone.
DB01232
The metabolism of Saquinavir can be increased when combined with Fluocortolone.
DB01238
The metabolism of Aripiprazole can be increased when combined with Fluocortolone.
DB01259
The metabolism of Lapatinib can be increased when combined with Fluocortolone.
DB01267
The metabolism of Paliperidone can be increased when combined with Fluocortolone.
DB04856
The metabolism of Dexloxiglumide can be increased when combined with Fluocortolone.
DB04946
The metabolism of Iloperidone can be increased when combined with Fluocortolone.
DB04957
The metabolism of Azimilide can be increased when combined with Fluocortolone.
DB05521
The metabolism of Telaprevir can be increased when combined with Fluocortolone.
DB06228
The metabolism of Rivaroxaban can be increased when combined with Fluocortolone.
DB06267
The metabolism of Udenafil can be increased when combined with Fluocortolone.
DB06403
The metabolism of Ambrisentan can be increased when combined with Fluocortolone.
DB06419
The metabolism of Cethromycin can be increased when combined with Fluocortolone.
DB06605
The metabolism of Apixaban can be increased when combined with Fluocortolone.
DB06652
The metabolism of Vicriviroc can be increased when combined with Fluocortolone.
DB06697
The metabolism of Artemether can be increased when combined with Fluocortolone.
DB08820
The metabolism of Ivacaftor can be increased when combined with Fluocortolone.
DB08873
The metabolism of Boceprevir can be increased when combined with Fluocortolone.
DB08883
The metabolism of Perampanel can be increased when combined with Fluocortolone.
DB08899
The metabolism of Enzalutamide can be increased when combined with Fluocortolone.
DB09061
The metabolism of Cannabidiol can be increased when combined with Fluocortolone.
DB09065
The metabolism of Cobicistat can be increased when combined with Fluocortolone.
DB09068
The metabolism of Vortioxetine can be increased when combined with Fluocortolone.
DB09102
The metabolism of Daclatasvir can be increased when combined with Fluocortolone.
DB09231
The metabolism of Benidipine can be increased when combined with Fluocortolone.
DB09237
The metabolism of Levamlodipine can be increased when combined with Fluocortolone.
DB09297
The metabolism of Paritaprevir can be increased when combined with Fluocortolone.
DB11574
The metabolism of Elbasvir can be increased when combined with Fluocortolone.
DB11586
The metabolism of Asunaprevir can be increased when combined with Fluocortolone.
DB11689
The metabolism of Selumetinib can be increased when combined with Fluocortolone.
DB11712
The metabolism of Tezacaftor can be increased when combined with Fluocortolone.
DB11737
The metabolism of Icotinib can be increased when combined with Fluocortolone.
DB11757
The metabolism of Istradefylline can be increased when combined with Fluocortolone.
DB11915
The metabolism of Valbenazine can be increased when combined with Fluocortolone.
DB11951
The metabolism of Lemborexant can be increased when combined with Fluocortolone.
DB12130
The metabolism of Lorlatinib can be increased when combined with Fluocortolone.
DB12161
The metabolism of Deutetrabenazine can be increased when combined with Fluocortolone.
DB12301
The metabolism of Doravirine can be increased when combined with Fluocortolone.
DB13952
The metabolism of Estradiol acetate can be increased when combined with Fluocortolone.
DB13955
The metabolism of Estradiol dienanthate can be increased when combined with Fluocortolone.
DB14011
The metabolism of Nabiximols can be increased when combined with Fluocortolone.
DB14185
The metabolism of Aripiprazole lauroxil can be increased when combined with Fluocortolone.
DB14541
The metabolism of Hydrocortisone cypionate can be increased when combined with Fluocortolone.
DB06448
The metabolism of Lonafarnib can be increased when combined with Fluocortolone.
DB14542
The metabolism of Hydrocortisone phosphate can be increased when combined with Fluocortolone.
DB09256
The metabolism of Tegafur can be increased when combined with Fluocortolone.
DB00091
Fluocortolone may increase the immunosuppressive activities of Cyclosporine.
DB13074
The therapeutic efficacy of Macimorelin can be decreased when used in combination with Fluocortolone.
DB00381
The metabolism of Amlodipine can be increased when combined with Fluocortolone.
DB00024
The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Fluocortolone.
DB00279
The therapeutic efficacy of Liothyronine can be decreased when used in combination with Fluocortolone.
DB00451
The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Fluocortolone.
DB01583
The therapeutic efficacy of Liotrix can be decreased when used in combination with Fluocortolone.
DB03604
The therapeutic efficacy of Tiratricol can be decreased when used in combination with Fluocortolone.
DB09100
The therapeutic efficacy of Thyroid, porcine can be decreased when used in combination with Fluocortolone.
DB00425
The metabolism of Zolpidem can be increased when combined with Fluocortolone.
DB00331
The therapeutic efficacy of Metformin can be decreased when used in combination with Fluocortolone.
DB00945
The risk or severity of adverse effects can be increased when Fluocortolone is combined with Acetylsalicylic acid.
DB11986
The metabolism of Entrectinib can be increased when combined with Fluocortolone.
DB01432
Cholestyramine may increase the excretion rate of Fluocortolone which could result in a lower serum level and potentially a reduction in efficacy.
DB00388
The risk or severity of hypertension can be increased when Fluocortolone is combined with Phenylephrine.
DB00357
The therapeutic efficacy of Fluocortolone can be decreased when used in combination with Aminoglutethimide.
DB01268
The risk or severity of hyperglycemia can be increased when Sunitinib is combined with Fluocortolone.
DB00030
The risk or severity of hyperglycemia can be increased when Fluocortolone is combined with Insulin human.
DB00046
The risk or severity of hyperglycemia can be increased when Fluocortolone is combined with Insulin lispro.
DB00047
The risk or severity of hyperglycemia can be increased when Fluocortolone is combined with Insulin glargine.
DB00071
The risk or severity of hyperglycemia can be increased when Fluocortolone is combined with Insulin pork.
DB00197
The risk or severity of hyperglycemia can be increased when Fluocortolone is combined with Troglitazone.
DB00222
The risk or severity of hyperglycemia can be increased when Fluocortolone is combined with Glimepiride.
DB00263
The risk or severity of hyperglycemia can be increased when Fluocortolone is combined with Sulfisoxazole.
DB00280
The risk or severity of hyperglycemia can be increased when Fluocortolone is combined with Disopyramide.
DB00284
The risk or severity of hyperglycemia can be increased when Fluocortolone is combined with Acarbose.
DB00359
The risk or severity of hyperglycemia can be increased when Fluocortolone is combined with Sulfadiazine.
DB00412
The risk or severity of hyperglycemia can be increased when Fluocortolone is combined with Rosiglitazone.
DB00414
The risk or severity of hyperglycemia can be increased when Fluocortolone is combined with Acetohexamide.
DB00468
The risk or severity of hyperglycemia can be increased when Fluocortolone is combined with Quinine.
DB00491
The risk or severity of hyperglycemia can be increased when Fluocortolone is combined with Miglitol.
DB00672
The risk or severity of hyperglycemia can be increased when Fluocortolone is combined with Chlorpropamide.
DB00731
The risk or severity of hyperglycemia can be increased when Fluocortolone is combined with Nateglinide.
DB00738
The risk or severity of hyperglycemia can be increased when Fluocortolone is combined with Pentamidine.
DB00839
The risk or severity of hyperglycemia can be increased when Fluocortolone is combined with Tolazamide.
DB00912
The risk or severity of hyperglycemia can be increased when Fluocortolone is combined with Repaglinide.
DB00914
The risk or severity of hyperglycemia can be increased when Fluocortolone is combined with Phenformin.
DB01016
The risk or severity of hyperglycemia can be increased when Fluocortolone is combined with Glyburide.
DB01067
The risk or severity of hyperglycemia can be increased when Fluocortolone is combined with Glipizide.
DB01120
The risk or severity of hyperglycemia can be increased when Fluocortolone is combined with Gliclazide.
DB01124
The risk or severity of hyperglycemia can be increased when Fluocortolone is combined with Tolbutamide.
DB01132
The risk or severity of hyperglycemia can be increased when Fluocortolone is combined with Pioglitazone.
DB01251
The risk or severity of hyperglycemia can be increased when Fluocortolone is combined with Gliquidone.
DB01252
The risk or severity of hyperglycemia can be increased when Fluocortolone is combined with Mitiglinide.
DB01261
The risk or severity of hyperglycemia can be increased when Fluocortolone is combined with Sitagliptin.
DB01276
The risk or severity of hyperglycemia can be increased when Fluocortolone is combined with Exenatide.
DB01277
The risk or severity of hyperglycemia can be increased when Fluocortolone is combined with Mecasermin.
DB01278
The risk or severity of hyperglycemia can be increased when Fluocortolone is combined with Pramlintide.
DB01289
The risk or severity of hyperglycemia can be increased when Fluocortolone is combined with Glisoxepide.
DB01306
The risk or severity of hyperglycemia can be increased when Fluocortolone is combined with Insulin aspart.
DB01307
The risk or severity of hyperglycemia can be increased when Fluocortolone is combined with Insulin detemir.
DB01309
The risk or severity of hyperglycemia can be increased when Fluocortolone is combined with Insulin glulisine.
DB01382
The risk or severity of hyperglycemia can be increased when Fluocortolone is combined with Glymidine.
DB01700
The risk or severity of hyperglycemia can be increased when Fluocortolone is combined with AICA ribonucleotide.
DB04830
The risk or severity of hyperglycemia can be increased when Fluocortolone is combined with Buformin.
DB04876
The risk or severity of hyperglycemia can be increased when Fluocortolone is combined with Vildagliptin.
DB04878
The risk or severity of hyperglycemia can be increased when Fluocortolone is combined with Voglibose.
DB05115
The risk or severity of hyperglycemia can be increased when Fluocortolone is combined with NN344.
DB05819
The risk or severity of hyperglycemia can be increased when Fluocortolone is combined with NBI-6024.
DB06011
The risk or severity of hyperglycemia can be increased when Fluocortolone is combined with AMG-222.
DB06127
The risk or severity of hyperglycemia can be increased when Fluocortolone is combined with Bisegliptin.
DB06203
The risk or severity of hyperglycemia can be increased when Fluocortolone is combined with Alogliptin.
DB06292
The risk or severity of hyperglycemia can be increased when Fluocortolone is combined with Dapagliflozin.
DB06335
The risk or severity of hyperglycemia can be increased when Fluocortolone is combined with Saxagliptin.
DB06655
The risk or severity of hyperglycemia can be increased when Fluocortolone is combined with Liraglutide.
DB08382
The risk or severity of hyperglycemia can be increased when Fluocortolone is combined with Gosogliptin.
DB08882
The risk or severity of hyperglycemia can be increased when Fluocortolone is combined with Linagliptin.
DB08907
The risk or severity of hyperglycemia can be increased when Fluocortolone is combined with Canagliflozin.
DB08962
The risk or severity of hyperglycemia can be increased when Fluocortolone is combined with Glibornuride.
DB09022
The risk or severity of hyperglycemia can be increased when Fluocortolone is combined with Benfluorex.
DB09038
The risk or severity of hyperglycemia can be increased when Fluocortolone is combined with Empagliflozin.
DB09043
The risk or severity of hyperglycemia can be increased when Fluocortolone is combined with Albiglutide.
DB09045
The risk or severity of hyperglycemia can be increased when Fluocortolone is combined with Dulaglutide.
DB09198
The risk or severity of hyperglycemia can be increased when Fluocortolone is combined with Lobeglitazone.
DB09199
The risk or severity of hyperglycemia can be increased when Fluocortolone is combined with Netoglitazone.
DB09200
The risk or severity of hyperglycemia can be increased when Fluocortolone is combined with Rivoglitazone.
DB09201
The risk or severity of hyperglycemia can be increased when Fluocortolone is combined with Ciglitazone.
DB09265
The risk or severity of hyperglycemia can be increased when Fluocortolone is combined with Lixisenatide.
DB09456
The risk or severity of hyperglycemia can be increased when Fluocortolone is combined with Insulin beef.
DB09564
The risk or severity of hyperglycemia can be increased when Fluocortolone is combined with Insulin degludec.
DB11567
The risk or severity of hyperglycemia can be increased when Fluocortolone is combined with Insulin peglispro.
DB11568
The risk or severity of hyperglycemia can be increased when Fluocortolone is combined with Insulin tregopil.
DB11698
The risk or severity of hyperglycemia can be increased when Fluocortolone is combined with Ipragliflozin.
DB11723
The risk or severity of hyperglycemia can be increased when Fluocortolone is combined with Dutogliptin.
DB11780
The risk or severity of hyperglycemia can be increased when Fluocortolone is combined with Allicin.
DB11824
The risk or severity of hyperglycemia can be increased when Fluocortolone is combined with Tofogliflozin.
DB11827
The risk or severity of hyperglycemia can be increased when Fluocortolone is combined with Ertugliflozin.
DB11898
The risk or severity of hyperglycemia can be increased when Fluocortolone is combined with 2,4-thiazolidinedione.
DB11950
The risk or severity of hyperglycemia can be increased when Fluocortolone is combined with Teneligliptin.
DB11992
The risk or severity of hyperglycemia can be increased when Fluocortolone is combined with Omarigliptin.
DB12268
The risk or severity of hyperglycemia can be increased when Fluocortolone is combined with Carmegliptin.
DB12412
The risk or severity of hyperglycemia can be increased when Fluocortolone is combined with Gemigliptin.
DB12417
The risk or severity of hyperglycemia can be increased when Fluocortolone is combined with Anagliptin.
DB12625
The risk or severity of hyperglycemia can be increased when Fluocortolone is combined with Evogliptin.
DB12713
The risk or severity of hyperglycemia can be increased when Fluocortolone is combined with Sotagliflozin.
DB12781
The risk or severity of hyperglycemia can be increased when Fluocortolone is combined with Balaglitazone.
DB12935
The risk or severity of hyperglycemia can be increased when Fluocortolone is combined with Remogliflozin etabonate.
DB13406
The risk or severity of hyperglycemia can be increased when Fluocortolone is combined with Carbutamide.
DB13446
The risk or severity of hyperglycemia can be increased when Fluocortolone is combined with Guar gum.
DB13675
The risk or severity of hyperglycemia can be increased when Fluocortolone is combined with Metahexamide.
DB13928
The risk or severity of hyperglycemia can be increased when Fluocortolone is combined with Semaglutide.
DB14027
The risk or severity of hyperglycemia can be increased when Fluocortolone is combined with Taspoglutide.
DB14035
The risk or severity of hyperglycemia can be increased when Fluocortolone is combined with Englitazone.
DB15171
The risk or severity of hyperglycemia can be increased when Fluocortolone is combined with Tirzepatide.
DB15217
The risk or severity of hyperglycemia can be increased when Fluocortolone is combined with Gastric inhibitory polypeptide.
DB01200
The risk or severity of hyperglycemia can be increased when Fluocortolone is combined with Bromocriptine.
DB00951
The serum concentration of Isoniazid can be decreased when it is combined with Fluocortolone.
DB01396
The risk or severity of adverse effects can be increased when Fluocortolone is combined with Digitoxin.
DB00390
The risk or severity of adverse effects can be increased when Fluocortolone is combined with Digoxin.
DB00511
The risk or severity of adverse effects can be increased when Fluocortolone is combined with Acetyldigitoxin.
DB01078
The risk or severity of adverse effects can be increased when Fluocortolone is combined with Deslanoside.
DB13401
The risk or severity of adverse effects can be increased when Fluocortolone is combined with Metildigoxin.
DB13467
The risk or severity of adverse effects can be increased when Fluocortolone is combined with Lanatoside C.
DB13537
The risk or severity of adverse effects can be increased when Fluocortolone is combined with Gitoformate.
DB13691
The risk or severity of adverse effects can be increased when Fluocortolone is combined with Acetyldigoxin.
DB04914
The therapeutic efficacy of G17DT can be decreased when used in combination with Fluocortolone.
DB05144
The therapeutic efficacy of PEV3A can be decreased when used in combination with Fluocortolone.
DB05325
The therapeutic efficacy of INGN 225 can be decreased when used in combination with Fluocortolone.
DB05374
The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Fluocortolone.
DB05440
The therapeutic efficacy of SRP 299 can be decreased when used in combination with Fluocortolone.
DB05942
The therapeutic efficacy of GI-5005 can be decreased when used in combination with Fluocortolone.
DB06400
The therapeutic efficacy of Vitespen can be decreased when used in combination with Fluocortolone.
DB06584
The therapeutic efficacy of TG4010 can be decreased when used in combination with Fluocortolone.
DB09057
The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Fluocortolone.
DB10062
The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Fluocortolone.
DB10076
The therapeutic efficacy of Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Fluocortolone.
DB10276
The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Fluocortolone.
DB10283
The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Fluocortolone.
DB10317
The therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Fluocortolone.
DB10318
The therapeutic efficacy of Varicella Zoster Vaccine (Live/attenuated) can be decreased when used in combination with Fluocortolone.
DB10342
The therapeutic efficacy of Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen can be decreased when used in combination with Fluocortolone.
DB10343
The therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with Fluocortolone.
DB10583
The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Fluocortolone.
DB10584
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Fluocortolone.
DB10600
The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Fluocortolone.
DB10769
The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Fluocortolone.
DB10794
The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) can be decreased when used in combination with Fluocortolone.
DB10803
The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Fluocortolone.
DB10804
The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Fluocortolone.
DB10805
The therapeutic efficacy of Yellow Fever Vaccine can be decreased when used in combination with Fluocortolone.
DB10989
The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Fluocortolone.
DB10990
The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Fluocortolone.
DB11003
The therapeutic efficacy of Anthrax vaccine can be decreased when used in combination with Fluocortolone.
DB11038
The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Fluocortolone.
DB11040
The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Fluocortolone.
DB11041
The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Fluocortolone.
DB11044
The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) can be decreased when used in combination with Fluocortolone.
DB11050
The therapeutic efficacy of Typhoid Vaccine Live can be decreased when used in combination with Fluocortolone.
DB11603
The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Fluocortolone.
DB11627
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Fluocortolone.
DB12386
The therapeutic efficacy of Bacillus calmette-guerin substrain danish 1331 live antigen can be decreased when used in combination with Fluocortolone.
DB12568
The therapeutic efficacy of Tecemotide can be decreased when used in combination with Fluocortolone.
DB12768
The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Fluocortolone.
DB13924
The therapeutic efficacy of Varicella Zoster Vaccine (Recombinant) can be decreased when used in combination with Fluocortolone.
DB14022
The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Fluocortolone.
DB14384
The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Fluocortolone.
DB14385
The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Fluocortolone.
DB14394
The therapeutic efficacy of Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen can be decreased when used in combination with Fluocortolone.
DB14409
The therapeutic efficacy of Human adenovirus e serotype 4 strain cl-68578 antigen can be decreased when used in combination with Fluocortolone.
DB14443
The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Fluocortolone.
DB14445
The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Fluocortolone.
DB14449
The therapeutic efficacy of Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen can be decreased when used in combination with Fluocortolone.
DB14619
The therapeutic efficacy of Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) can be decreased when used in combination with Fluocortolone.
DB14620
The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Fluocortolone.
DB14685
The therapeutic efficacy of Adenovirus type 7 vaccine live can be decreased when used in combination with Fluocortolone.
DB14711
The therapeutic efficacy of Smallpox (Vaccinia) Vaccine, Live can be decreased when used in combination with Fluocortolone.
DB15274
The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Fluocortolone.
DB15461
The therapeutic efficacy of Yersinia pestis 195/p antigen (formaldehyde inactivated) can be decreased when used in combination with Fluocortolone.
DB15483
The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Fluocortolone.
DB15595
The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Fluocortolone.
DB15654
The therapeutic efficacy of Moderna COVID-19 Vaccine can be decreased when used in combination with Fluocortolone.
DB06119
The serum concentration of Cenobamate can be decreased when it is combined with Fluocortolone.
DB01364
Ephedrine may increase the excretion rate of Fluocortolone which could result in a lower serum level and potentially a reduction in efficacy.
DB00052
The therapeutic efficacy of Somatotropin can be decreased when used in combination with Fluocortolone.
DB01320
The serum concentration of Fosphenytoin can be decreased when it is combined with Fluocortolone.
DB00252
The serum concentration of Fluocortolone can be decreased when it is combined with Phenytoin.
DB14513
The serum concentration of Magnesium can be decreased when it is combined with Fluocortolone.
DB01601
The serum concentration of Fluocortolone can be increased when it is combined with Lopinavir.
DB00503
The serum concentration of Ritonavir can be increased when it is combined with Fluocortolone.
DB00232
The risk or severity of electrolyte imbalance can be increased when Fluocortolone is combined with Methyclothiazide.
DB00436
The risk or severity of electrolyte imbalance can be increased when Fluocortolone is combined with Bendroflumethiazide.
DB00562
The risk or severity of electrolyte imbalance can be increased when Fluocortolone is combined with Benzthiazide.
DB00774
The risk or severity of electrolyte imbalance can be increased when Fluocortolone is combined with Hydroflumethiazide.
DB00880
The risk or severity of electrolyte imbalance can be increased when Fluocortolone is combined with Chlorothiazide.
DB00999
The risk or severity of electrolyte imbalance can be increased when Fluocortolone is combined with Hydrochlorothiazide.
DB01021
The risk or severity of electrolyte imbalance can be increased when Fluocortolone is combined with Trichlormethiazide.
DB01324
The risk or severity of electrolyte imbalance can be increased when Fluocortolone is combined with Polythiazide.
DB13532
The risk or severity of electrolyte imbalance can be increased when Fluocortolone is combined with Cyclopenthiazide.
DB00606
The risk or severity of electrolyte imbalance can be increased when Fluocortolone is combined with Cyclothiazide.
DB13430
The risk or severity of electrolyte imbalance can be increased when Fluocortolone is combined with Mebutizide.
DB00502
The serum concentration of Haloperidol can be increased when it is combined with Fluocortolone.
DB11652
The metabolism of Tucatinib can be decreased when combined with Fluocortolone.
DB12530
The risk or severity of infection can be increased when Fluocortolone is combined with Inebilizumab.
DB11932
The serum concentration of Fluocortolone can be increased when it is combined with Abametapir.
DB15762
The serum concentration of Fluocortolone can be decreased when it is combined with Satralizumab.
DB15093
The serum concentration of the active metabolites of Fluocortolone can be decreased when Fluocortolone is used in combination with Somapacitan.
序列
实验性质
Melting Point
180-182
U.S. Patent 3,426,128.
外部标识符
resource:ChEBI
identifier:135581
resource:PubChem Compound
identifier:9053
resource:PubChem Substance
identifier:310264934
resource:ChemSpider
identifier:8701
resource:Wikipedia
identifier:Fluocortolone
resource:ChEMBL
identifier:CHEMBL251634
resource:ZINC
identifier:ZINC000004213353
resource:RxCUI
identifier:4463
外部链接
路径
目标
BE0002638Cytochrome P450 3A4HumanssubstrateinducerA18131620482443Dvorak Z, Pavek P: Regulation of drug-metabolizing cytochrome P450 enzymes by glucocorticoids. Drug Metab Rev. 2010 Nov;42(4):621-35. doi: 10.3109/03602532.2010.484462.T308978-1-4441-4752-0Grayson L., Crowe S., Hope W., McCarthy J., Mills J., Mouton J., Paterson D., Paterson D. and Pfaller M. (2010). Kucers' the use of antibiotics (6th ed.). Taylor and Francis Group.noCytochrome P450 3A4Vitamin d3 25-hydroxylase activityCytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,8-cineole 2-exo-monooxygenase. The enzyme also hydroxylates etoposide (PubMed:11159812). Catalyzes 4-beta-hydroxylation of cholesterol. May catalyze 25-hydroxylation of cholesterol in vitro (PubMed:21576599).CYP3A47q21.1Endoplasmic reticulum membrane2-228.2557342.677HumansHUGO Gene Nomenclature Committee (HGNC)HGNC:2637GenAtlasCYP3A4GenBank Gene DatabaseM18907Guide to Pharmacology1337UniProtKBP08684UniProt AccessionCP3A4_HUMAN1,8-cineole 2-exo-monooxygenase1.14.13.-Albendazole monooxygenaseAlbendazole sulfoxidaseCholesterol 25-hydroxylaseCYP3A3CYPIIIA3CYPIIIA4Cytochrome P450 3A3Cytochrome P450 HLpCytochrome P450 NF-25Cytochrome P450-PCN1Nifedipine oxidaseQuinine 3-monooxygenaseTaurochenodeoxycholate 6-alpha-hydroxylase>lcl|BSEQ0021936|Cytochrome P450 3A4 MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNILSYHKGFCMF DMECHKKYGKVWGFYDGQQPVLAITDPDMIKTVLVKECYSVFTNRRPFGPVGFMKSAISI AEDEEWKRLRSLLSPTFTSGKLKEMVPIIAQYGDVLVRNLRREAETGKPVTLKDVFGAYS MDVITSTSFGVNIDSLNNPQDPFVENTKKLLRFDFLDPFFLSITVFPFLIPILEVLNICV FPREVTNFLRKSVKRMKESRLEDTQKHRVDFLQLMIDSQNSKETESHKALSDLELVAQSI IFIFAGYETTSSVLSFIMYELATHPDVQQKLQEEIDAVLPNKAPPTYDTVLQMEYLDMVV NETLRLFPIAMRLERVCKKDVEINGMFIPKGVVVMIPSYALHRDPKYWTEPEKFLPERFS KKNKDNIDPYIYTPFGSGPRNCIGMRFALMNMKLALIRVLQNFSFKPCKETQIPLKLSLG GLLQPEKPVVLKVESRDGTVSGA>lcl|BSEQ0021937|Cytochrome P450 3A4 (CYP3A4) ATGGCTCTCATCCCAGACTTGGCCATGGAAACCTGGCTTCTCCTGGCTGTCAGCCTGGTG CTCCTCTATCTATATGGAACCCATTCACATGGACTTTTTAAGAAGCTTGGAATTCCAGGG CCCACACCTCTGCCTTTTTTGGGAAATATTTTGTCCTACCATAAGGGCTTTTGTATGTTT GACATGGAATGTCATAAAAAGTATGGAAAAGTGTGGGGCTTTTATGATGGTCAACAGCCT GTGCTGGCTATCACAGATCCTGACATGATCAAAACAGTGCTAGTGAAAGAATGTTATTCT GTCTTCACAAACCGGAGGCCTTTTGGTCCAGTGGGATTTATGAAAAGTGCCATCTCTATA GCTGAGGATGAAGAATGGAAGAGATTACGATCATTGCTGTCTCCAACCTTCACCAGTGGA AAACTCAAGGAGATGGTCCCTATCATTGCCCAGTATGGAGATGTGTTGGTGAGAAATCTG AGGCGGGAAGCAGAGACAGGCAAGCCTGTCACCTTGAAAGACGTCTTTGGGGCCTACAGC ATGGATGTGATCACTAGCACATCATTTGGAGTGAACATCGACTCTCTCAACAATCCACAA GACCCCTTTGTGGAAAACACCAAGAAGCTTTTAAGATTTGATTTTTTGGATCCATTCTTT CTCTCAATAATCTTTCCATTCCTCATCCCAATTCTTGAAGTATTAAATATCTGTGTGTTT CCAAGAGAAGTTACAAATTTTTTAAGAAAATCTGTAAAAAGGATGAAAGAAAGTCGCCTC GAAGATACACAAAAGCACCGAGTGGATTTCCTTCAGCTGATGATTGACTCTCAGAATTCA AAAGAAACTGAGTCCCACAAAGCTCTGTCCGATCTGGAGCTCGTGGCCCAATCAATTATC TTTATTTTTGCTGGCTATGAAACCACGAGCAGTGTTCTCTCCTTCATTATGTATGAACTG GCCACTCACCCTGATGTCCAGCAGAAACTGCAGGAGGAAATTGATGCAGTTTTACCCAAT AAGGCACCACCCACCTATGATACTGTGCTACAGATGGAGTATCTTGACATGGTGGTGAAT GAAACGCTCAGATTATTCCCAATTGCTATGAGACTTGAGAGGGTCTGCAAAAAAGATGTT GAGATCAATGGGATGTTCATTCCCAAAGGGGTGGTGGTGATGATTCCAAGCTATGCTCTT CACCGTGACCCAAAGTACTGGACAGAGCCTGAGAAGTTCCTCCCTGAAAGATTCAGCAAG AAGAACAAGGACAACATAGATCCTTACATATACACACCCTTTGGAAGTGGACCCAGAAAC TGCATTGGCATGAGGTTTGCTCTCATGAACATGAAACTTGCTCTAATCAGAGTCCTTCAG AACTTCTCCTTCAAACCTTGTAAAGAAACACAGATCCCCCTGAAATTAAGCTTAGGAGGA CTTCTTCAACCAGAAAAACCCGTTGTTCTAAAGGTTGAGTCAAGGGATGGCACCGTAAGT GGAGCCTGAPF00067p450componentcytoplasmcomponentendoplasmic reticulum membranecomponentintegral component of membranecomponentintracellular membrane-bounded organellefunctionalbendazole monooxygenase activityfunctionaromatase activityfunctioncaffeine oxidase activityfunctionenzyme bindingfunctionheme bindingfunctioniron ion bindingfunctionmonooxygenase activityfunctionoxidoreductase activityfunctionoxygen bindingfunctionquinine 3-monooxygenase activityfunctionsteroid bindingfunctionsteroid hydroxylase activityfunctiontaurochenodeoxycholate 6alpha-hydroxylase activityfunctiontestosterone 6-beta-hydroxylase activityfunctionvitamin D 24-hydroxylase activityfunctionvitamin D3 25-hydroxylase activityprocessalkaloid catabolic processprocessandrogen metabolic processprocesscalcitriol biosynthetic process from calciolprocessdrug catabolic processprocessdrug metabolic processprocessexogenous drug catabolic processprocessheterocycle metabolic processprocesslipid metabolic processprocessmonoterpenoid metabolic processprocessoxidation-reduction processprocessoxidative demethylationprocesssmall molecule metabolic processprocesssteroid catabolic processprocesssteroid metabolic processprocessvitamin D metabolic processprocessxenobiotic metabolic processunknownBE0002362Cytochrome P450 3A5HumansinducerA18131620482443Dvorak Z, Pavek P: Regulation of drug-metabolizing cytochrome P450 enzymes by glucocorticoids. Drug Metab Rev. 2010 Nov;42(4):621-35. doi: 10.3109/03602532.2010.484462.unknownCytochrome P450 3A5Oxygen bindingCytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.CYP3A57q21.1Endoplasmic reticulum membrane9.0957108.0657HumansHUGO Gene Nomenclature Committee (HGNC)HGNC:2638GenAtlasCYP3A5GenBank Gene DatabaseJ04813GenBank Protein Database181346Guide to Pharmacology1338UniProtKBP20815UniProt AccessionCP3A5_HUMAN1.14.14.1CYPIIIA5Cytochrome P450 HLp2Cytochrome P450-PCN3>lcl|BSEQ0004639|Cytochrome P450 3A5 MDLIPNLAVETWLLLAVSLVLLYLYGTRTHGLFKRLGIPGPTPLPLLGNVLSYRQGLWKF DTECYKKYGKMWGTYEGQLPVLAITDPDVIRTVLVKECYSVFTNRRSLGPVGFMKSAISL AEDEEWKRIRSLLSPTFTSGKLKEMFPIIAQYGDVLVRNLRREAEKGKPVTLKDIFGAYS MDVITGTSFGVNIDSLNNPQDPFVESTKKFLKFGFLDPLFLSIILFPFLTPVFEALNVSL FPKDTINFLSKSVNRMKKSRLNDKQKHRLDFLQLMIDSQNSKETESHKALSDLELAAQSI IFIFAGYETTSSVLSFTLYELATHPDVQQKLQKEIDAVLPNKAPPTYDAVVQMEYLDMVV NETLRLFPVAIRLERTCKKDVEINGVFIPKGSMVVIPTYALHHDPKYWTEPEEFRPERFS KKKDSIDPYIYTPFGTGPRNCIGMRFALMNMKLALIRVLQNFSFKPCKETQIPLKLDTQG LLQPEKPIVLKVDSRDGTLSGE>lcl|BSEQ0016766|Cytochrome P450 3A5 (CYP3A5) ATGGACCTCATCCCAAATTTGGCGGTGGAAACCTGGCTTCTCCTGGCTGTCAGCCTGGTG CTCCTCTATCTATATGGGACCCGTACACATGGACTTTTTAAGAGACTGGGAATTCCAGGG CCCACACCTCTGCCTTTGTTGGGAAATGTTTTGTCCTATCGTCAGGGTCTCTGGAAATTT GACACAGAGTGCTATAAAAAGTATGGAAAAATGTGGGGAACGTATGAAGGTCAACTCCCT GTGCTGGCCATCACAGATCCCGACGTGATCAGAACAGTGCTAGTGAAAGAATGTTATTCT GTCTTCACAAATCGAAGGTCTTTAGGCCCAGTGGGATTTATGAAAAGTGCCATCTCTTTA GCTGAGGATGAAGAATGGAAGAGAATACGGTCATTGCTGTCTCCAACCTTCACCAGCGGA AAACTCAAGGAGATGTTCCCCATCATTGCCCAGTATGGAGATGTATTGGTGAGAAACTTG AGGCGGGAAGCAGAGAAAGGCAAGCCTGTCACCTTGAAAGACATCTTTGGGGCCTACAGC ATGGATGTGATTACTGGCACATCATTTGGAGTGAACATCGACTCTCTCAACAATCCACAA GACCCCTTTGTGGAGAGCACTAAGAAGTTCCTAAAATTTGGTTTCTTAGATCCATTATTT CTCTCAATAATACTCTTTCCATTCCTTACCCCAGTTTTTGAAGCATTAAATGTCTCTCTG TTTCCAAAAGATACCATAAATTTTTTAAGTAAATCTGTAAACAGAATGAAGAAAAGTCGC CTCAACGACAAACAAAAGCACCGACTAGATTTCCTTCAGCTGATGATTGACTCCCAGAAT TCGAAAGAAACTGAGTCCCACAAAGCTCTGTCTGATCTGGAGCTCGCAGCCCAGTCAATA ATCTTCATTTTTGCTGGCTATGAAACCACCAGCAGTGTTCTTTCCTTCACTTTATATGAA CTGGCCACTCACCCTGATGTCCAGCAGAAACTGCAAAAGGAGATTGATGCAGTTTTGCCC AATAAGGCACCACCTACCTATGATGCCGTGGTACAGATGGAGTACCTTGACATGGTGGTG AATGAAACACTCAGATTATTCCCAGTTGCTATTAGACTTGAGAGGACTTGCAAGAAAGAT GTTGAAATCAATGGGGTATTCATTCCCAAAGGGTCAATGGTGGTGATTCCAACTTATGCT CTTCACCATGACCCAAAGTACTGGACAGAGCCTGAGGAGTTCCGCCCTGAAAGGTTCAGT AAGAAGAAGGACAGCATAGATCCTTACATATACACACCCTTTGGAACTGGACCCAGAAAC TGCATTGGCATGAGGTTTGCTCTCATGAACATGAAACTTGCTCTAATCAGAGTCCTTCAG AACTTCTCCTTCAAACCTTGTAAAGAAACACAGATCCCCTTGAAATTAGACACGCAAGGA CTTCTTCAACCAGAAAAACCCATTGTTCTAAAGGTGGATTCAAGAGATGGAACCCTAAGT GGAGAATGAPF00067p450componentendoplasmic reticulum membranecomponentintracellular membrane-bounded organellefunctionaromatase activityfunctionheme bindingfunctioniron ion bindingfunctionmonooxygenase activityfunctionoxidoreductase activityfunctionoxygen bindingprocessalkaloid catabolic processprocessdrug catabolic processprocessoxidative demethylationprocesssmall molecule metabolic processprocesssteroid metabolic processprocessxenobiotic metabolic processunknown
载体
运输工具
药物反应
效应
不良反应